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Abstract 
 
The dissertation describes the synthesis of sulfonylimine ligands from N-sulfonylpyrrole. 
These ligands form metal complexes with various transition metals and are to be tested 
for activity against cancer cells. The introductory chapter sets the scene by describing 
transition metals in existing therapy and current investigations on transition metals in 
therapy. It also covers current methodology for deprotonation of N-sulfonylpyrrole 
leading to carbon-carbon bond formation. 
 
The second chapter describes the experimental work performed in this project. A 
synthetic route towards sulfonylimine ligands, 4-methyl-N-[phenyl(1H-pyrrol-
2yl)methylene]benzenesulfonamide 15 and N-[phenyl(1H-pyrrol-
2yl)methylene]benzenesulfonamide  6, is described. The mechanism for the 1,4-
migration of the sulfonyl group was investigated in a crossover experiment and was 
found to occur via an intra molecular shift. 
 
The sulfonylimine ligands were complexed with late transition metals from the first row 
(cobalt(II), nickel(II), copper (I), copper(II) and zinc(II)), second row (palladium(II) and 
silver(I))and third  row (platinum(II)), and were submitted for testing against cancer cells. 
The first row transition metal complexes did not show activity against HeLa cancer cells, 
while in the second row, activity was observed for the silver complexes. The third row 
metal complex also showed anti-cancer activity. 
 
Previously reported methodology employing Grignard reagent and catalytic amine base 
to deprotonate N-sulfonylpyrrole and quenching with electrophiles was extended to 
indole, imidazole and benzimidazole ring systems. Results obtained were comparable to 
those reported using lithium bases. Addition of lithium chloride to the Grignard reagent 
reduces the mole equivalent of the reagent required for deprotonation.  
  
 
A comparison between the arylsulfonyl and dimethylsulfamoyl protecting groups in 
pyrrole and imidazole showed that arylsulfonyl are better protecting groups for pyrrole, 
while dimethylsulfamoyl is a better protecting group for imidazole. 
 
All synthesized organic structures were characterized by NMR spectral data, mass 
spectrometry and melting points where applicable. The synthesized metal complexes 
were characterized by mass spectroscopy, infrared spectroscopy and X-ray 
crystallography where applicable. 
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Chapter 1:         Introduction 
 
1.1 Background on transition metals in biological systems 
 
Transition metals play essential roles in the functioning of physiological life. They 
participate in important biological functions, e.g. iron (Fe) in hemoglobin, cobalt (Co) in 
vitamin B12, molybdenum (Mo) in the molybdenum cofactor (Moco)1, just to mention a 
few.  Deficiency in these essential transition metals leads to serious illness and in some 
cases death. Not all transition metals, however, are used biologically. This is due to their 
bioavailability; nature appears to prefer metals that are easily obtained from the soil.  
 
Transition metals that are bioavailable include manganese (Mn), iron (Fe), cobalt (Co), 
copper (Cu), zinc (Zn) and the second row metal molybdenum (Mo)2. Much research is 
currently focused on making complexes which contain these essential transition metals 
and testing their activity against various diseases. The research involves collaboration of 
various disciplines in the field of science e.g. chemistry and biochemistry.  
 
A brief overview containing current transition metals in therapy and current 
investigations of transition metals in therapy is given below. 
 
1.2 Background on transition metals in therapy 
 
1.2.1 Existing transition metal-based therapy 
 
Transition metals that are not bioavailable have also been investigated for activity against 
various diseases. The most useful complex is without doubt cisplatin 1, discovered in the 
1960s3, used in the treatment of cancer. The complex contains a platinum metal bonded 
to two nitrogen ligands and two chlorine ligands. The mode of action of cisplatin is 
believed to involve the binding of the complex into the two DNA strands, blocking 
  
replication and transcription of nucleic acids into proteins. It has also been shown to 
trigger programmed cell death (apoptosis)1. Other findings in this research show that the 
platinum complex binds to one DNA strand and causes distortion that results in cell 
death4-6. 
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Figure 1. Cisplatin (1) 
 
Cisplatin is currently being used for the treatment of cancer, and has shown high activity 
against various cancer cell lines. The IC50 value, the concentration of a drug required to 
kill 50% of infected cells, is below 5 µM in most cell lines. The drug 1 has shown side 
effects such as nephrotoxicity, neurotoxicity, vomiting and nausea. Other cancer cell lines 
are resistant to cisplatin7-8. These limitations have led to research into finding drugs that 
are as active as, or more active than, cisplatin but with fewer side effects.  
 
Gold compounds have also been used in therapy. The use of gold in medicine can be 
dated back to 2500 B.C.9-10 where it has been used to treat leprosy, epilepsy and other 
diseases.  
 
In 1928 gold-thiolate drugs (Figure 2) found their use in the treatment of rheumatoid 
arthritis (RA) and even today they are still used9. These drugs contain gold in its +1 
oxidation state and act as anti-inflammatory agents. However, they have been shown to 
have severe side effects and are only used as a last line of defense. Treatment of RA in 
the early stages usually involves more conventional organic drugs known as non-steroid 
anti-inflammatory agents (NSAIDs) and corticosteroids. The NSAIDs drugs act by 
blocking cyclooxygenase enzymes, COX-1 and COX-2, and in turn block prostaglandins 
generated by the COX enzymes. The prostaglandins are important mediators for both 
pain and inflammation9. The corticosteroids act as anti-inflammatory and 
immunoregulatory agents.  
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Figure 2. Gold-thiolate drugs 
 
1.2.1 Current investigations into transition metals as therapeutic agents 
 
Much research is currently focused on making transition metal complexes that contain 
both the bioavailable and non-bioavailable transition metals and many publications have 
shown some of these complexes to have some biological activity.  
 
Cobalt complexes have shown anti-malarial effects11 where they target the plasmodium 
parasite. The activity of the compounds was comparable to that of the currently used 
drug, amodiaquine, at similar concentrations (Figure 3 a). These studies were in vitro 
studies and only show the toxicity to the parasite not the host. No further biological 
testing information was reported. Other studies have shown cobalt complexes to have 
anti-bacterial activity which is also comparable to the presently available drug, 
imipenium12. These results were also done in vitro and there is no mention of further 
biological testing on these compounds (Figure 3 b). Cobalt is a redox active metal where 
the +2 and +3 oxidation states are most common.  
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Figure 3. An example of cobalt complexes used in anti-malaria (a) and anti-bacteria 
(b) studies.  
 
Molybdenum complexes (e.g. Figure 4) have shown anti-cancer activity13 against the cell 
line, V79 Chinese hamster lung cells. These complexes were used to study the 
relationship between cellular uptake and toxicity and were only performed in vitro. 
Unlike most transition metals in biological systems, Mo has a high oxidation state of +6 
and a high coordination number.  
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Figure 4. An example of a molebdenum complex used in an anti-cancer study. 
 
A number of synthetic copper complexes have been shown to have anti-malarial 
activity11, anti-cancer activity14-15, nuclease activity16, anti-inflammatory activity in 
rheumatoid arthritis17, and they also catalyse several reactions, such as nitration of 
aromatic compounds, which are usually catalysed by the enzyme superoxide dismutase18. 
The mode of action of these complexes is unclear and both oxidation states of the metal, 
i.e. +1 and +2, are used. Promising results have been observed from both oxidation states. 
These reported results were performed in vitro and there appear to be no further mention 
of other biological testing. 
  
Zinc complexes have been shown to bind strongly to an HIV receptor CXCR4, used for 
membrane fusion, and hence inhibit the spread of the virus19. The complexes were shown 
to be ten times more active than the metal-free ligand, showing the importance of the 
metal (Figure 5). Other zinc complexes have been shown to have anti-malarial activity11 
and also anti-bacterial activity12 in similar studies to those of cobalt.  
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Figure 5. An example of a Zn complex used in an anti-HIV study. 
 
Many platinum-containing complexes (e.g. Figure 6) have since been synthesized, after 
cisplatin, and some have shown promising results 7, 20-22. The focus has been in trying to 
incorporate ligands that are similar to those in biological systems and also less toxic. 
Other platinum complexes have been shown to have anti-HIV activity23. Complexes 
containing metals that are isoelectronic to platinum(II), i.e. palladium(II) and gold(III) 
have also been investigated for their activity against cancer. 
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Figure 6. An example of a platinum complex used in an anti-cancer study. 
 
 Palladium complexes (e.g. Figure 7) have shown anti-cancer activity similar to their 
platinum counterparts7,23 and in some cases have been more active than cisplatin24. Pd(II) 
is a d8 ion which has square planar geometry around the metal, similar to Pt(II). In 
catalysis the processes catalysed by platinum can also be catalysed by palladium and in 
some cases palladium is better25. 
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Figure 7. An example of a palladium complex used in an anti-cancer study. 
 
Gold complexes (e.g. Figure 8) have also shown anti-cancer activity but, interestingly, 
both oxidation states of gold, i.e. +1 and +3 have shown activity23- 30. The different 
oxidation states of the gold metal have been shown to direct the metal to different target 
areas, Au(I) complexes have been shown to interact strongly with the mitochondria, 
while Au(III) has been shown to interact with the DNA with a mechanism suggested to 
be related to that of cisplatin the platinum complexes31. 
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Figure 8. An example of a gold complex used in an anti-cancer study.  
 
The use of silver in medicine has been known for some time. For example, silver nitrate 
(AgNO3) has been used as an anti-microbial agent since the 1800s. Silver complexes 
have also shown anti-cancer19, 31-32 and anti-malarial activity11, and in other experiments 
silver complexes were more active when compared to the platinum and palladium 
complexes. Nickel complexes have also shown significant activity against certain cancer 
cell lines33-34. 
 
1.2.3 Toxicity 
 
Although some transition metal complexes have shown activity against several diseases, 
most of the results obtained were from in vitro studies. This type of study involves only 
affected cells and no information about healthy cells can be obtained. When in vivo or 
  
clinical tests are performed, most of the metal complexes have been shown to be toxic to 
healthy cells and thus not effective for the treatment of a particular disease. In most cases, 
the infected cells and the normal cells are very similar i.e. they have similar DNA, 
protein, RNA structure and other molecules essential for the functioning of the cells1. The 
difference between healthy cells and infected cells is usually the disruption of one 
pathway which leads to overproduction or underproduction of certain molecules which 
result in disease. Cancer cells have been shown to be more metabolically active than 
normal cells and this result in cancer cells replicating faster than normal cells and 
spreading over a large area in the body1. 
 
It is important to have compounds that are selective for only the infected cells but not the 
healthy ones. This helps in minimizing side effects. The way of achieving this goal is to 
identify the major difference between the normal and infected cell, then target those 
specific areas in the cell. Cisplatin targets the DNA of the cancer cells since they replicate 
faster than normal cells and hence minimize the spread of the cancer cells35. It should be 
noted that the mode of action of most of these metal complexes is not known and thus it 
is difficult to make target-specific metal complexes.  
 
Transition metals in their free ion form are toxic and not target-specific. They also have a 
high risk of being excreted by the kidneys before they can be absorbed by the cells. Other 
metal salts e.g. Au(CN)2- are insoluble and have to be administered orally. One way of 
making soluble target-specific metal complexes is by ligand design. 
 
1.3 Background on ligand design 
 
Designing a ligand is one of the challenging parts of drug design since many variables are 
involved. These variables include polarity, size, shape and metal binding ability and 
strength. The polarity of the ligand must be able to allow the metal complex to be soluble 
in the host medium, which is aqueous and also be able to interact with the cell membrane 
which is mainly hydrophobic1, 36. Once the drug is on the membrane it should be able 
pass through into the cell or it must interact with the membrane receptors and induce 
  
other physiological pathways. This requires the metal complex to have polar groups that 
can interact with the aqueous medium and also non-polar groups to interact with the 
hydrophobic portion of the cell membrane36. 
 
The balance between the polar and non-polar properties of the molecule is measured by 
the log p value (equation 1), which measures the concentration of the molecule in the 
organic phase versus the aqueous phase36. This is obtained by dissolving a known amount 
of the compound in a solvent mixture of water and octanol, shaking the mixture and 
measuring the concentration in both phases. 
 
                log p =        Concentration of compound in octanol                         (1)     
                             Concentration of compound in aqueous solution 
 
The higher the value of log p, the more non-polar the compound will be, and vice versa. 
It has been shown that compounds with a high log p value are more biologically active 
than those with lower values36. This may be due to the compounds(low log p) being too 
polar and not being able to pass through the membrane, resulting in their excretion by the 
kidneys1, 36. The range of log p value shown to be effective is between +1 and +5. Above 
+5, the molecule is very non-polar and not soluble in the aqueous medium but gets 
absorbed by the fat tissues instead. This results in the molecule not reaching its target and 
subsequently getting excreted without performing its intended function36. 
 
The size of the molecule must not be too large since this tends to increase the number of 
polar groups attached on the molecule. The molecular weight of the molecule should be 
less than 500 g/mol, but this value is difficult to obtain with metal complexes since 
metals have high coordination number and require more than one ligand. Transition 
metals also have high molecular weights per atom which results in the overall complex 
being heavy. If the complex has a high molecular weight then it should also have a high 
log p value to make the complex less polar36. 
 
  
The shape of the ligand plays a very important role in making the molecule target-
specific since a target area requires specific geometry of substrates. Drugs targeting the 
DNA are planar and disrupt the DNA replication by intercalating with the double strand. 
Proteins usually require a 3-D structure to bind in their active site and hence the 
molecules need not to be planar but must have a size similar to those that naturally bind 
the active site of the protein36. Metal complexes are usually too large to compete for the 
active site of proteins and they probably target areas away from or near the active site and 
modify activity by an allosteric mechanism1. 
 
The ability of the ligand to bind the metal and form a stable complex is extremely 
important and will determine if the complex will survive in biological solution, which 
contains a large pool of molecules capable of complexing metals. The molecules include 
the amino acids, nucleotides and carbohydrates which contain OH, NH and SH groups 
that can coordinate with metals1, 2 ,36. It is extremely important to design ligands that will 
form strong interactions with metals when compared to interactions with other biological 
ligands. A strong metal-ligand interaction ensures that the complex will have a high 
binding constant. This is usually achieved by using appropriate chelating ligands chosen 
on the basis of hard-soft acid-base (HSAB) theory. 
 
Chelating ligands have two or more donor atoms in the molecule, which can bind the 
metal ion at the same time2. This is very useful since it reduces the number of molecules 
coordinating to the metal centre. Chelating ligands have been shown to form stable 
complexes with metals when compared to non-chelating ligands. This is due to less 
repulsion around the metal since the number of molecules around the metal centre is 
reduced. Also of importance are the kinetics of formation of the metal-chelate complex, 
which are usually fast compared with a non-chelate-metal complex2. 
 
The hard-soft acid-base (HSAB) theory states that soft metals (Lewis acids) will form 
strong interactions with soft ligand donors (Lewis bases), and likewise hard metals with 
hard ligand donors2. Soft metals and ligand donors are those with a polarisable electron 
density cloud around the nucleus, while hard metals and ligand donors have an 
  
unpolarised electron cloud. Hard metals are found in the top and left of the periodic table 
and metals become softer when moving to the left and bottom of the periodic table. High 
oxidation states favour hard metals while soft are favoured by low oxidation states.  
 
Hard donor ligands are often those with oxygen donor groups and their strength increases 
with the negative charge on the oxygen, and also fluorine and chlorine. Soft donor 
ligands are those with phosphorus, bromine, iodine and in rare cases carbon ligands. 
Other donor atoms such as nitrogen and sulfur have been shown to be intermediate in 
their bonding strength. They form stable complexes with both the hard and soft metals2. 
 
Most of the transition metals being investigated for biological activity are those found in 
the right and bottom of the periodic table, hence they are soft or slightly soft in nature. 
Most of the ligands designed for complexing these metals are chelating and contains 
intermediate to soft donor ligands depending on the nature of the metal. Most of these 
ligands contain at least one nitrogen donor atom and in other cases all the donor atoms 
are nitrogen atoms. 
 
 Very soft metals such as gold(I), silver(I) and copper(I) are usually complexed with soft 
donor ligands containing  nitrogen, sulfur or phosphorus atoms4, 23, 24, 27, 28 and 29. The 
slightly soft metals such as Pt(II), Pd(II), Ni(II), Cu(II), Zn(II), Co(II) and Au(III) form 
strong interactions with nitrogen and sulfur donor atoms, but in some cases oxygen donor 
atoms can be used11, 29, 31-32.  
 
Many synthetic transition metal complexes are being investigated for their anti-cancer 
activity, but synthesizing a particular molecule with specific target areas is very difficult 
since the causes of cancer are very diverse and hence there are many target areas 
involved1, 37-38.  
 
 
 
 
  
1.4 Background on cancer 
 
Cancer is a disease caused by cells with uncontrollable cell growth37.  This uncontrollable 
growth is caused mainly by two factors, i.e., cells not responding to growth factors, and 
overproduction or underproduction of various proteins responsible for growth regulation. 
Growth factors (GFs) are molecules which send signal to cells to start or stop cell 
division and also to undergo programmed cell death (a process known as apoptosis) when 
the cells are damaged or old1, 37 -38.  These GFs ranges from small organic molecules to 
small peptide molecules such as hormones. 
 
When cells overproduce proteins responsible for cell division, e.g. DNA polymerase, the 
DNA of the cell will continuously replicate and this will lead to uncontrollable cell 
division. Other proteins that can be overproduced are those that signal the start of cell 
division. Underproduction of proteins that stop cell division or induce apoptosis also 
results in uncontrollable cell division or growth38. 
 
More than 90% of all cancer is caused by the damage to the cell DNA, which is 
responsible for the production of all proteins in the cell39. Damage to the DNA is caused 
by mutations and cleavage of DNA fragments. Mutations can arise from a change of one 
nucleotide to another, e.g. guanine (G) to thymine (T), or cytosine (C ) to uracil (U). 
They can also occur due to the translocation between chromosomes. The resulting 
mutations result in a change in the genes responsible for protein coding and synthesis, 
resulting in modified proteins being produced. These modified proteins may perform 
different functions compared to the normal ones and, in the worst cases, change the cell 
from being normal to a cancer cell37-39.  
 
DNA damages occur naturally and can also be induced by environmental factors known 
as carcinogens, which are: 
(i) Physical agents (radiation), 
(ii) Chemical agents (organic compounds), and 
(iii) Infectious agents (viruses). 
  
Radiations, e.g. X-rays, have been shown to cleave DNA, and when DNA repair occurs, 
mutations are likely to occur. In other cases the DNA is not repaired and as a result other 
proteins are no longer produced. Chemical agents cause mutations by altering the DNA 
sequence where one nucleotide is replaced by another. In other cases, the nucleotide is 
methylated and is no longer recognized by the replicating enzymes, resulting in loss of 
protein production40. The role of viruses in the cause of cancer is not fully known but it is 
believed that the virus DNA gets incorporated into the host DNA and in other cases the 
virus produces proteins that inhibit apoptosis38. 
 
DNA from natural cells has been shown to undergo mutations even when not exposed to 
environmental factors causing cancer. The history of cancer has been known since 
humans first learnt to record their activities38 but it used to be an old-age disease. As 
humans grown old, the rate of DNA mutations increases, since their DNA has replicated 
so many times. The rate of mutation for normal cells, however, is very low compared to 
cells exposed to carcinogens40.  High occurrence of cancer in human is also observed in 
infants since their cells replicate faster than adult cells thus high rate of mutations is 
possible.                                
 
Since most metal-complexes are too large to mimic molecules binding to the active site 
of enzymes, their target area is mainly on the DNA. These molecules need to be planar 
for them to be effective since they should intercalate with the DNA strands and stop 
DNA replication. Planar metal complexes must have a square planar geometry in the 
metal centre, as well as planar ligands. Planar ligands are made from aromatic 
compounds and since coordinating atoms are required, heteroaromatic compounds are 
usually used. 
 
 
 
 
 
 
  
1.5 Introduction to this project 
 
1.5.1 Synthesis of N-phenylsulfonylimine ligands 
 
The N-phenylsulfonylimine ligands were synthesized in our laboratory by Patil and 
Mandy41 in an effort to generate precursors for azinomycin synthesis. The most 
demanding step in azinomycin synthesis is the generation of a densely functionalized 
pyrolidine-aziridine ring system42, which has been previously synthesized from 
carbohydrate precursors. An alternative disconnection of the pyrolidine ring 2 leads to 
azafulvene synthon 3 or its tautomeric form of pyrrole 4 (Scheme 1).  
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Scheme 1. 
 
Azafulvenes are intermediates in a number of reactions but they are highly reactive 
molecules43-45. They undergo rapid dimerisation43,44 and also react with various 
nucleophiles42. Azafulvene species are formed from electron rich pyrrole molecules43-45. 
Introducing an electron-withdrawing group (EWG) into a pyrrole ring, on the nitrogen 
atom, suppresses the formation of azafulvene42.  This has led to exploration into using 
electron deficient pyrrole systems as alternative to azafulvenes. 
 
The EWG chosen in our laboratory was the phenylsulfonyl group, which also has an 
additional advantage of being a directing ortho metallation (DOM) group. Phenylsulfonyl 
chloride, source of the phenylsulfonyl group, is crystalline in nature, and this crystallinity 
is usually transferred to molecules bearing the sulfonyl group. The sulfonyl group can be 
introduced into a pyrrole, in a presence of base (Scheme 2), to give N-
phenylsulfonylpyrrole 5. Itahara et al.46 made use of sodium hydride in DMF, Gaare et 
al.47 made use of LDA, Ottoni et al.48 made use of potassium hydroxide and Anderson49, 
  
Artico50 and Zelikin51 all made use of sodium hydroxide under varying conditions. The 
sulfonyl group can be easily removed under basic hydrolytic conditions (Scheme 2) with 
sodium hydroxide52, sodium methoxide53, and potassium hydroxide49 or potassium 
carbonate54. 
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Scheme 2. 
 
Dinsmore et al.55 explored the functionalization of pyrrole 5 using magnesiation 
conditions, where the pyrrole was deprotonated at the 2-position and various electrophiles 
were introduced. Patil and Mandy41 made use of lithium bases to deprotonate pyrrole 5 
and various electrophiles were introduced, but of importance were the nitrile electrophiles 
as they give products that could be potential precursors to azinomycin synthesis. 
Unexpectedly, these workers found that nitrile electrophiles allows a 1,4-migration of the 
sulfonyl group, believed to occur via intra-molecular process, from the pyrrole into the 
imine (Scheme 3) and thus make products similar to 4. 
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Scheme 3. 
 
The 1,4-migration was first observed from the reaction of lithiated N-
phenylsulfonylindole with benzonitrile, where 2-ketoindole was isolated. The product is 
believed to have occurred from the hydrolysis of the imine (not isolated or characterized) 
into a ketone, following the 1,4-migration (Scheme 4). Unlike the indole reaction, Patil 
  
and Mandy41 found that the hydrolysis step does not occur with pyrrole when subjected to 
similar conditions as indole. 
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Scheme 4. 
 
In an attempt to generate methodology for making 4, lithiated pyrrole 5 was reacted with 
benzonitrile to give the N-phenylsulfonylimine 6 and an amidine product 7 (Scheme 5). 
The formation of the amidine product involves an inter-molecular step whereby the 
sulfonyl group is transferred from the sulfonylpyrrole 2. These results suggests that the 
rates of intra- and inter-molecular steps might be comparable, and also the 1,4-migrartion 
of the sulfonyl group might proceed via the suggested intra-molecular shift and also via 
the inter-molecular shift. 
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Scheme 5. 
 
1.5.2 Crossover experiment 
 
To investigate the 1,4-migration of the sulfonyl, an experiment which involved mixing a 
lithiated sulfonyl pyrrole 5 and a lithiated substituted N-toluenesulfonylpyrrole, then 
quenching with benzonitrile (Scheme 6), was attempted. In their attempt, Patil and 
Mandy41 tried to substitute the pyrrole hydrogen of N-toluenesulfonylpyrrole 8, with 
deuterium. Their hypothesis was as follows: exclusive production of products designated 
  
A and C will support the intramolecular shift while if in addition to A and C, products B 
and D are detected, then the intermolecular mechanism will be taking place as well.  Due 
to the inability to label the pyrrole ring appropriately, the crossover experiment was not 
performed. A successful completion of such a crossover experiment is described in this 
thesis. 
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Scheme 6. 
 
1.5.3 Metal Complexes 
 
The N-phenylsulfonylimine 6 was investigated for its ability to complex metal ions via its 
two nitrogen atoms, thus acting as a bidentate ligand. Complexes with copper(II) 9, 
copper(I) 10 and palladium(II) 11 (Figure 9) were synthesized by Patil and Mandy41. 
These complexes were tested for anti-cancer activity and promising results were 
observed, where IC50 values were below 10 µM in in vitro assays.   
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Figure 9. Metal complexes previously synthesized in our laboratory. 
 
The less soft metals, i.e. Cu (II) and Pd (II) were chelated with two ligands while the 
more soft metal contains one chelate ligand and two soft phosphine ligands. Complex 10 
was more active than 9, indicating that the phosphine ligands may enhance the activity of 
the complex. The complexes are prepared by treating pyrrole 6 and a metal salt in a 
presence of a base. The palladium complex 11 was also tested for catalytic activity in the 
Heck-type coupling reaction between iodobenzene and an activated sulfonylpyrrole. No 
activity was observed as only the starting materials were recovered without any trace of 
products. 
 
1.5.4 Magnesium amide bases in C-C bond formation 
 
N-Heterocyclic compounds, e.g. pyrrole, indole, imidazole, pyridine, are very important 
in organic synthesis, where they serve as starting materials. These compounds are able to 
form a carbon-carbon bond, which is one of the most important steps in organic 
synthesis56. A popular way of making a C-C bond is by nucleophilic electrophilic 
reaction. The N-heterocyclic compounds contain acidic protons that can be extracted by a 
  
base and generate a nucleophilic carbon that can then react with an electrophilic carbon 
making a C-C bond. 
 
Although N-heterocyclic compounds may have acidic protons, their pkas are high such 
that normal bases can not deprotonate them. Very strong bases are used to deprotonate 
these compounds, and the most commonly used bases are the lithium bases R-Li (R= 
alkyl or amide)43. Many lithiation reactions have been performed on pyrrole56-60, indole56, 
60
 and imidazole56, 61-62, with subsequent quenching with electrophiles resulting in a C-C 
bond formation. The heterocyclic compounds are first protected at the nitrogen atom to 
remove the more acidic N-H proton thus leaving the acidic C-H proton available for 
deprotonation (Scheme 7).   
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Scheme 7.         X=H, pyrrole; X=N, imidazole, R = protecting group and R’= alkyl 
 
Organolithium bases react irreversibly with many electrophiles and as a result they are 
very unstable. They react with moisture forming LiOH and RH and at this stage the base 
is no longer effective. Their storage requires inert atmosphere and low temperatures. 
Their reactions also require very low temperatures, e.g. –78 °C, since the reactions are 
very exothermic. Low temperatures also help in reducing the number of side reactions 
that can occur since these bases can also react with other functional groups present in the 
molecule, leading to undesired products. An alternative to using lithium bases is the use 
of magnesium bases. 
 
Magnesium is mainly used as a constituent of Grignard reagents, RMgX (R= alkyl, aryl, 
ect.; X = Cl, Br), and these reagents are widely used in C-C bond formation reactions63. 
  
These reagents contain a carbon metal bond which is a good nucleophile for C-C bond 
formation but, unlike lithium reagents, they are not good bases for deprotonating 
heterocyclic compounds. Grignard reagents are usually converted into amides or 
bisamides (Scheme 8), which are good bases for deprotonating acidic protons on a 
carbon. Various methods used are shown below 
 
     
      i)         2R2NH  +  Mg            
heat or current
   Mg(NR2)2  + H264 
        
ii)         Hg(NR2)2 + Mg             Mg(NR2)2  + Hg65 
      iii)       2RMgNR’2                    Mg(NR’2)2  + MgR266 
iv) Mg(NR2)2 + 2R’2NH     Mg(NR’2)2  + 2R2NH67 
v) 2R2NH  + R’2Mg           Mg(NR2)2  + 2R’H68 
vi) R2NH  + R’MgX            R2NMgX  + 2R’H69 
 
Scheme 8. 
 
The bis(amides) have been shown to deprotonate acidic protons from ketones and also 
from benzene rings without reacting with the functional groups present (Scheme 5), 
showing greater functional group tolerance than lithium reagents70- 75.  
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Scheme 9. 
 
  
Work by Kondo et al. showed that in addition to magnesium bis(amide) bases, 
magnesium amides (known as Hauser bases) can be used to deprotonate heterocyclic 
protons76-77. N-protected indoles, which are reactive at the 3-position, were deprotonated 
exclusively at the 2-position using diisopropylaminomagnesium chloride (iPr2NMgCl) 
12, and quenched with different electrophiles76 (Scheme 10).  
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Scheme 10. 
 
Thiophenes and thiazoles, containing functional groups, were also deprotonated at the 2-
position using 1277
 
(Scheme 11). These reactions, unlike lithium reactions, were 
performed at ambient temperature and the yields obtained were comparable. 
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Scheme 11. 
 
  
By realizing that the active species in deprotonation is the magnesium amide species, 
Dinsmore et al., successfully used diisopropylamine in catalytic amounts with respect to 
the Grignard reagent55. N-Phenylsulfonylpyrrole 5 was deprotonated at the 2-position 
using this method, and different electrophiles were introduced in moderate to good yields 
(Scheme 12). 
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Scheme 12. 
 
The downfall of using Hauser bases is the formation of dimers, where there is bridging in 
the chlorides. This was determined from the crystal structure, determined by Power, of  
[(Me3Si)2NMgCl.(Et2O)]2 (Figure 10)78. A large excess of the base, as high as 355, is used 
as a result of this dimer formation.   
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Figure 10.  
 
In an attempt to reduce the base equivalent amount, Knochel et al., very recently found 
that adding lithium chloride (LiCl) to the Grignard reagent isopropylmagnesium chloride 
(iPrMgCl) 13, reduces the amount of the reagent required in a reaction79- 81. The new 
Grignard reagent isopropylmagnesium chloride-lithium chloride (iPrMgCl.LiCl) 14, has 
been shown to be superior to 13 in I/Mg exchange reactions (Scheme 13). The LiCl is 
  
believed to prevent dimer formation and thus providing monomers of the Grignard 
species81. 
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Scheme 13. 
 
Hauser bases containing lithium chloride have also been prepared with a general formula, 
R2NMgCl.LiCl82-83. These bases were shown to be superior to normal Hauser bases and 
lithium bases in that they required fewer equivalents of base (1.1 eq.) and their yields 
were generally higher. These bases were used in the deprotonation of benzene substrates 
bearing different functional groups82 (Scheme 14), and also with several heterocyclic 
compounds83. These bases are used at ambient temperatures and can tolerate a wide range 
of functional groups.  
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Scheme 14. 
 
The drawbacks in using these new Grignard reagent is that they are not atom economic. 
Equivalent amount of LiCl, Mg and TMP are required to prepare the base and thus the 
cost of preparing these bases is high. 
 
 
 
  
1. 6 Aims of this project. 
 
The aims of the project are: 
i) To investigate the mechanism behind the 1,4-migration of the 
sulfonyl group, 
ii) To make more metal complexes using N-toluenesulfonylimine 
ligand and to test the complexes for anti-cancer activity, 
iii) To extend the scope of magnesiation, developed by Dinsmore55, to 
other N-heteraromatic compounds, and finally to try to improve the 
magnesiation conditions reported by Knochel82-83, by making use of 
catalytic amine. 
These aims are described in detail below. 
 
1.6.1 Investigating the 1,4-migartion of the sulfonyl group 
 
The approach in determining the mechanism was intended to be very similar to the one 
attempted by Patil and Mandy41. Instead of substituting the pyrrole protons with 
deuterium, a different substituent was to be introduced in the 2-position of N-
toluenesulfonylpyrrole 8. The substituent introduced must not be reactive under lithiating 
conditions, and a few that attracted our attention were the trimethylsilyl group (SiMe3), 
the methyl group (Me) and the phenyl group. Once the 2-substituted pyrrole 8 has been 
made, it will be mixed with pyrrole 5, lithiated, quenched with benzonitrile and the 
resulting products characterized (Scheme 15). 
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Scheme 15. 
 
1.6.2 Metal complexes with N-toluenesulfonylimine ligands 
 
We were interested in synthesizing metal complexes containing the chelate N-
toluenesulfonylimine ligand 15 in order to test their activity against cancer cells. We were 
mostly interested in the late second and third row transition metals, i.e. Pt(II), Pd(II), 
Ag(I), and Au(III) since they have previously shown good activity against cancer cells. 
The first row transition metals, i.e. Co(II), Ni(II), Cu(I) and Cu(II), and Zn(II) were also 
considered in the study. The ligand 15 (Figure 11) is very similar to the 
phenylsulfonylimine ligand 6 with the only difference being the presence of toluyl 
instead of phenyl group. The ligand contains a sulfonamide portion which, for many 
years, has been used as an anti-bacterial drug84.  
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Figure  11. The sulfonylimine ligand to be used for complexation in this project.                                              
 
The initial approach will be to repeat the complexes made with ligand 6, using ligand 15, 
then after methodology has been established, more transition metal complexes will be 
synthesized. We aim to expand the range of these complexes by making Pt(II) 16, Ag(I) 
17, Co(II) 18, Ni(II) 19, Zn(II) 20 and Au(III) 21. We aim to chelate the soft Ag metal 
with one ligand and two phosphine ligands, while the rest we aim to chelate with two 
ligands (Figure 12). 
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Figure 12. Metal complexes intended to be synthesized in this project. 
 
1.6.3 Comparing the magnesiation conditions reported by Dinsmore55 and 
Knochel82-83 
 
Although these new generation Hauser bases (described in section 1.5.2) are very 
effective, the cost of making them is high. Equimolar amounts of LiCl, TMP or iPr2NH 
and iPrMgCl are needed. We aim to investigate whether LiCl and/or the amine bases can 
used in catalytic amounts, as described by Dinsmore et al.55, and see if the same 
efficiency can be obtained. Our investigation will start using N-phenylsulfonylpyrrole 5 
  
as a substrate, comparing results to those from Dinsmore, then moving to other N-
heterocyclic compounds, i.e., indole, imidazole, benzimidazole, quinoline and pyridine.  
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Chapter 2:             Results and Discussion 
 
2.1.Ligand synthesis 
 
We started by first preparing the N-protected pyrrole, using a variation of the method of 
Zelikin et al51. Adding pyrrole to a suspension of dichloromethane and sodium hydroxide 
then adding, dropwise, arylsulfonyl chloride to the mixture, stirring overnight at room 
temperature gave N-toluenesulfonylpyrrole 8 in 81% yield and N-phenylsulfonyl pyrrole 
5 in 50% yield (Scheme 16). Spectroscopic data and melting points of our products were 
all consistent with those reported previously41,51. Later X-ray crystal structures of 
compounds derived from pyrrole 8 also confirmed the formation of the product 8 (see 
later).   
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Scheme 16. 
 
With the N-toluenesulfonylpyrrole 8 in hand, we then proceeded to the addition reaction 
with benzonitrile. The starting material requires deprotonation by means of very strong 
bases and our first choice was the lithium bases. Previous work by Patil and Mandy41 
employed lithiumdiisopropylamide (LDA) and lithium-tetramethylpiperidine (LiTMP) to 
deprotonate pyrrole 5 with subsequent quenching with benzonitrile to give the 
sulfonylimine 6. Our attention was drawn to the mention of butyllithium as a base to 
deprotonate N-phenylsulfonylimidazole 22 at –20 °C (Scheme 17)61. We were interested 
in using butyllithium to deprotonate pyrroles 5 and 8 and compare the results with those 
from imidazole. 
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Scheme 17. 
 
Treating pyrrole 8 with butyllithium and quenching with benzonitrile gave the desired 
product 4-methyl-N-[phenyl(1H-pyrrol-1yl)methylene]benzenesulfonamide 15 in 60% 
yield. Treating pyrrole 5 with n-BuLi and quenching with benzonitrile gave N-
[phenyl(1H-pyrrrol-1yl)methylene]benzenesulfonamide 6 in 30% yield (Scheme 18). 
These results were similar to those reported by Patil and Mandy41 and to our delight no 
side products resulting from the reaction of benzonitrile with butyllithium were observed. 
The amidine 7 (Chapter 1, section 1.5.1) was observed as a side product, resulting from 
the reaction of LDA and benzonitrile, by Patil and Mandy41. 
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Scheme 18. 
 
Mass spectroscopy showed the correct molecular ion [M+ 324 for 6 and 310 for 15] and 
the fragment ion [169 (M+ - SO2Ar] was observed for both products. This was also 
supported by 1H NMR spectrum, in which a peak at 10.16, corresponding to an N-H peak 
was, observed. A crystal structure of 6 was obtained (Appendix 1), confirming the 
formation of the desired products.  
 
With the idea of extending the sulfonyl transfer chemistry, we examined the possible 
reaction between lithiated imidazole 22 and benzonitrile (Scheme 19) but, to our 
disappointment, only the starting materials were obtained. The lithiation of 22 and 
  
subsequent reaction with electrophiles, has been reported to be in low yields61 and this 
could be the reason as to why no products were observed. The failure of imidazole 22 to 
react with benzonitrile meant that it could not be used in the study of the sulfonyl shift 
mechanism.   
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Scheme 19. 
 
2.2 Crossover experiment 
 
Having made the desired ligands, 6 and 15, we then investigated the mechanism by which 
the sulfonyl group migrates. We were interested in making 2-substituted pyrrole, where 
the substituent placed must be able to tolerate harsh conditions, such as those of n-BuLi. 
The functional groups investigated were the trimethylsilyl (TMS), methyl (Me) and 
phenyl (Ph). 
 
The first substituent to be investigated was the trimethylsilyl (Me3Si) group, after it was 
shown to be stable under lithiating conditions61. Treating pyrrole 8 consecutively with n-
BuLi and trimethylsilyl chloride (TMS-Cl) gave the 2-trimethylsilytoluenesufonylpyrrole 
23, but the product could not be separated from the disilylated and trisilylated product 
(Scheme 20). This was shown from mass spectrometry where peaks [M+ 294.12 
corresponding to 23, 366.12 corresponding to disilylated product and 438.12 
corresponding to trisilylated product] were observed on analysis of the crude product. 
Attempts to purify the products by chromatography and distillation failed to give 23 in a 
pure form. 
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Scheme 20. 
 
 
    
We then attempted to make 2-methyltoluenesulfonylpyrrole 24 by treating 8 with n-BuLi 
and methyl iodide (MeI). The product was obtained in reasonable yield (75% from 1H 
NMR spectroscopy) but it could not be separated from unreacted starting material 
regardless of the purification techniques (Scheme 21). The product and the starting 
material have the same Rf value in all solvents examined, thus chromatography could not 
separate them. Attempts to recrystallize the mixture failed to separate the compounds as 
crystals contained both compounds.     
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Scheme 21.                 
 
Treating 8 with iPrMgCl/ 5% iPr2NH and MeI reduced the yield (15%) of 24 as shown by 
1H NMR spectroscopy (Scheme 21). This suggest that full deprotonation of 8 is required 
for the clean production of 24. We then turned our attention to phenyl group as a marker 
on the pyrrole ring. 
 
Three routes to a 2-phenylated sulfonylpyrrole were investigated and compared. These 
were either (i) an investigation of recently published novel, and very attractive methods 
to allow the regiospecific Pd-catalysed arylation of electron rich heterocycles and (ii) a 
  
comparison of these with the Pd-catalysed phenylation of a magnesiated sulfonylpyrrole, 
methodology that was previously developed in our laboratory55. 
                                                    
The first method was a modification of a method reported by Sames85, in which the 
electron rich N-heterocyclic compounds i.e., pyrrole, indole and imidazole, were treated 
with catalytic tetrakis(triphenylphosphine)palladium [Pd(Ph3P)4] and MgO with refluxing 
in dioxane to afford 2-phenylated products in good yields. This method does not require 
an activated carbon, where in most cases a carbon-halogen bond is required for C-C bond 
coupling. When subjecting pyrrole 8 to the same conditions, no product was obtained. 
Our initial explanation was that free pyrrole is needed for these conditions since it is  
electron-rich. We then treated free pyrrole under the same conditions but only managed 
to get 3% yield of the product, 2-phenylpyrrole 25 (Scheme 22 condition a). It later 
emerged, following communications with the authors, that these reactions must be 
performed in a glove box under strictly anhydrous conditions for them to work. 
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Scheme 22. 
 
The second method is a two step reaction in which free pyrrole is first converted into 2-
phenylpyrrole 25, after which sulfonation would provide the desired pyrrole 26 (Scheme 
22 condition b). This method also does not require an activated carbon site. The first 
example was reported by Sanford86 who employed ambient conditions. PdCl2 or 
Pd(OAc)2, which are stable to air, are used instead of the air sensitive Pd(Ph3P)4. These 
Pd salts have an oxidation state of +2 and are suggested to undergo a +2/+4 oxidation 
change, unlike the 0/+2 oxidation state change that is involved in the coupling 
reactions86,87. The phenyl source diphenyliodonium-tetrafluoroborate [Ph2I]BF4 is 
different from the usual Ph-I or Ph-B(OH)2. Ph2I+ is described as an oxidative source of 
  
phenyl and it is suggested that it this allows the Pd to cycle between oxidation state 2 and 
4 during the course of the catalytic reaction. The reactions are done at room temperature 
as compared to the first method, where high temperatures (~150 oC) are required 
 
We began by preparing the phenyl source [Ph2I]BF4, which is made by the method of 
Skulski88, using a one pot synthesis (Scheme 23). Iodobenzene is first oxidized by 
chromium trioxide (CrO3) and sulfuric acid (H2SO4) in a solvent mixture of acetic acid 
(AcOH) and acetic anhydride (Ac2O). Acidic coupling with benzene followed by 
washing with aqueous potassium iodide (KI) gave the diphenyliodonium iodide ([Ph2I]I) 
27 in 50% yield. The melting point of the solid (162-163 oC) and its mass spectrometry 
data [M+ 281 corresponding to (Ph2I)+] were in agreement with the literature88. Treating 
pyrrole with 27 and PdCl2 in AcOH yielded no product and this was due to the 
insolubility of 27 in AcOH. We then converted 27 into a more soluble diphenyliodonium 
tetrafluoroborate [Ph2I]BF4 28, by adding HBF4 and H2O2 to 27 dissolved in methanol89 
(Scheme 23). The more soluble product 28 was obtained in 94% yield and its melting 
point (134 oC) was in agreement with literature89.  
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Scheme 23. 
 
Treating pyrrole with 28 and PdCl2 in AcOH gave 26 in 40% yield but it require a large 
ratio of pyrrole to 28 (10: 1) due to pyrrole having two reactive sites. Trace amounts of 
diphenylated pyrrole were also detected by mass spectrometry. When subjecting indole to 
the same conditions, the ratio of indole to 28 changes to (1: 2) since indole has only one 
reactive site in this reaction86. The requirement of a large excess of pyrrole means that 
starting with one gram of pyrrole will yield 84 mg of product and this is certainly not 
very economical. 
 
  
The third method requires the activation of carbon but, unlike most activation where a 
carbon-halogen bond is required, the method uses a carbon-magnesium bond. This was 
first reported by Dinsmore et al 55, who showed that treating 5 with iPrMgCl/ 5% iPr2NH 
to deprotonate, followed by catalytic Pd(Ph3P)4 and iodobenzene permitted arylation to 
occur (Scheme 24). When treating 8 to the same conditions, 26 was obtained in 51% 
yield. The melting point (123-124 oC) and molecular mass ion spectrum [M+ 298] were in 
agreement with literature values90. The reactions are done at room temperature and can 
also be extended to other N-heterocyclic compounds, to be discussed later. This method, 
when compared to above mentioned methods, is superior.  It does not require a glove box 
and high temperatures as in method 1. The phenyl source is easily obtainable and it is not 
required in large excess as in method 2.  By this method we were able to prepare gram 
quantities of pyrrole 26. 
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Scheme 24. 
 
Having made 26, we then subjected it to the lithiating conditions used to make 6 and 15, 
and to our delight, (E)-4-methyl-N-[phenyl(5-phenyl-1H-pyrrol-2-
yl)methylene]benzenesulfonamide 29 was obtained in 36% yield (Scheme 25). The 1H 
NMR spectrum showed the presence of two pyrrole C-H protons and also a peak at 10.81 
belonging to NH. Mass spectrometry showed the correct parent peak [M+ 400] and the 
fragmentation [245 (M+- SO2Tol)].  
 
                              
N
SO2Tol
Ph HN
N
Ph
SO2Toli)n-BuLi
ii) PhCN Ph
29
 
Scheme 25. 
 
  
A crystal structure was also obtained, confirming that the correct product has been made 
(Figure 13, appendix 2). The crystal structure shows that 29 was obtained as a solvate 
solid with acetone. The results also show the geometry around the C=N bond to be E. 
 
Figure 13. Crystal structure of the sulfonylimine 29. 
 
With the required starting materials for a cross-over experiment and with three of the four 
expected products fully characterized, it was time to perform the experiment (Scheme 15, 
chapter 1). Treating 5 and 26, in 1:1 ratio, with n-BuLi at –20 °C and benzonitrile gave 
two fractions after purification by chromatography and they were characterized by mass 
spectrometry (Scheme 26). The first fraction collected had a parent peak [M+ 310 (60) 
which correspond to 6], no peak at 324 corresponding to 15 was observed. The second 
fraction had a parent peak [M+ 400 (65) corresponding to 29]. No peak at 386 was 
observed and this led to the conclusion that the sulfonyl shift occurs mainly via the 1,4-
intramolecular migration and the intermolecular migration can be neglected (Scheme 27). 
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Scheme 26. 
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Scheme 27. 
 
With the ligands synthesized and the mechanism of formation investigated, we then 
proceeded to making metal complexes.   
 
 
2.3 Metal complexes 
 
The first row transition metals were the ideal starting point since they are cheaper  
compared to the second and third row metals. The copper complexes were the first to be 
made since preparations of structurally related complexes (complexes 9 and 10, Figure 9) 
have been reported by Patil and Mandy41. Patil reported the synthesis of copper(II) 
complex (9)  and Mandy reported the synthesis of copper(I) complex (10). 
 
Copper(II) complex 30 was prepared by treating sulfonylimine 15 with copper(II)acetate, 
in the presence of the base DBU, and refluxing in methanol (Scheme 28). The product 
was obtained as dark green crystals which were not suitable for diffraction but were 
  
characterized by mass spectrometry and infrared spectroscopy (IR). NMR spectroscopy 
could not be used to characterize the complex since it contains a spin active d9 metal. 
Mass spectrometry showed a parent peak at m/z 732 [M + Na]+ and m/z 710 [M + H]+ and 
fragmentations [347 and 324 corresponding to the ligand + Na+ and ligand + H+, 
respectively]. The IR spectrum showed the disappearance of the N-H stretch but no other 
obvious peak caused by the metal complexation could be observed. Elemental analysis 
data were also in agreement with the formation of the product.  
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Scheme 28. 
 
Copper(I) complex 31 was prepared by treating sulfonylimine 15 with DBU and 
CuBr(PPh3)3 in chloroform (Scheme 29). The product was obtained as yellow crystals 
suitable for X-ray diffraction (Figure 14, appendix 3).  
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Scheme 29. 
The complex has two triphenylphosphine ligands in addition to the chelating ligand 15. 
The geometry around the copper atom is tetrahedral as expected for d9 metal ions. The 
disappearance of the N-H proton was confirmed by 1H NMR and IR spectroscopy. The 
mass spectrometry data were very interesting because the molecular ion peak [M]+ was 
not observed either by FAB or ESI MS analysis. Peaks that were observed were m/z 587 
[M – ligand]+ i.e. Cu(PPh3)2+ and m/z 325 [CuPPh3]+, and these peaks were obtained in 
both ESI and FAB. This can be explained by the HSAB theory2 since Cu(I) is a soft 
  
Lewis acid and phosphorus is a soft Lewis base compared to nitrogen. The Cu-P 
interactions will weaken the Cu-N bond causing the bond to break off easily. This was 
also observed with the silver (I) complexes, to be discussed later. 
 
Figure 14. Crystal structure of the copper(I) complex. 
 
Synthesis of the nickel(II) complex 19 followed that for the preparation of 30. Treating 
sulfonylimine 15 with DBU and nickel(II) chloride did not give the desired product even 
after increasing the reflux time. Replacing the NiCl2 salt with the more reactive nickel(II) 
acetylacetonate gave the desired product as light green crystals (Scheme 30) which were 
not suitable for X-ray diffraction. 1H NMR spectroscopy show that the complex is spin 
active, indicating that the geometry around the metal is tetrahedral instead of square 
planar as experienced by most d8 metal ions2. Other studies of Ni, coordinated to four 
nitrogen atoms, have reported tetrahedral geometry around the metal centre91. Square 
planar complexes of Ni are favored by soft donor ligands, while tetrahedral is favored by 
intermediate to hard donor ligands2. IR spectroscopy showed the disappearance of the N-
H stretch, while mass spectroscopy gave two parent peaks at m/z 727 [M + Na]+ and m/z 
705 [M + H]+. A fragment peak at m/z 381 [M – ligand]+ was also observed. From these 
results we concluded that the desired compound was made. 
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Scheme 30. 
 
An attempt to make the Co complex 18 following the above procedure, and entailing 
treatment of sulfonylimine 15 with DBU and cobalt(II)chloride-hydrate (CoCl2.6H2O) 
gave an unexpected product, CoL2DBU 31, which in addition to the two chelating ligands 
around the metal, also include the base DBU coordinating the metal through nitrogen 
(Scheme 31). 
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Scheme 31. 
 
 A crystal structure of the compound was obtained (Figure 15, appendix 4), showing the 
two chelating ligands in an equatorial position and the DBU occupying the axial position. 
Mass spectrometry also gave a parent peak at m/z 858 [M + H]+, confirming the 
formation of complex 32. Attempts to make complex 18 by removing DBU gave no 
products, indicating the importance of a base in the reaction. The crystal structure shows 
that complex 32 was obtained as a solute with dichloromethane.  
  
 
Figure 15. Crystal structure of cobalt(II) complex. 
 
 
 
Similarly to the cobalt(II) complex, the intended zinc(II) complex 20 was never obtained 
after treating the ligand with DBU and zinc(II) chloride, ZnL2DBU 33 (Figure 16) was 
obtained instead. Mass spectrometry gave the parent peak at m/z 863 [M]+ and the 
fragments [711, 539 and 387 corresponding to ZnL2, ZnLDBU and ZnL, respectively] 
were also observed. The isotopic distribution of the parent ion agreed with a simulated 
distribution. The IR spectrum showed the disappearance of the N-H bond.  
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Figure 16. Line drawing structure of the zinc(II) complex. 
 
  
Having investigated the late first row transition metals, we then investigated the ability of 
the ligands to coordinate to late second and third row transition metals i.e. Pd, Ag, Pt and 
Au.  The Pd complex 34 was synthesized, using a variation of the method of Mandy41, 
where the ligand 15 is treated with sodium acetate and Li2[PdCl2Br2]  in methanol to give 
the product as a yellow solid. Attempts to recrystallize the solid were not successful as 
the compound was not soluble at room temperature in all solvents examined. Solubility 
was only observed in hot solvents but the product precipitated as small crystalline 
particles as soon as the solvent cooled down and as a result the crystal structure of the 
complex was not obtained. Mass spectrometry showed the parent peak  at m/z 775 [M + 
Na]+ and the IR spectrum showed the disappearance of the N-H peak, leading us to 
conclude the desired product had been formed (Scheme 32). 
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Scheme 32. 
Attempts to make a silver complex containing only the chelate ligand were unsuccessful. 
When ligand 15 was treated with silver nitrate in methanol according to the method of 
Fenton92 no product was obtained. We then reasoned that since Ag(I) is a soft metal an 
addition of a soft ligand might enhance the binding of the chelate ligand. We then treated 
15 with DBU, silver nitrate and triphenylphosphine and refluxed in methanol hoping to 
make 17, the analogue of the copper complex 10 and 31. A different compound AgLPPh3 
35 was formed instead of the desired product (Scheme 33). 
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Scheme 33. 
  
 The complex has the Ag metal with a coordination number of three, as shown by the 
crystal structure (Figure 17, appendix 5), where the chelate ligand is present with one 
triphenylphosphine. Metal complexes containing Ag with a coordination number of three 
have also been reported in the work of Fenton92. Mass spectrometry showed similar 
results to those obtained on the copper(I) complex 31; the molecular ion peak was not 
observed but the fragment at m/z 369 [AgPPh3]+ was observed. Another interesting peak 
at m/z 633 [Ag(PPh3)2]+ was also observed. ESI mass spectrometry studies on the 
complex, showed the presence of more additional species present in solution. In the 
negative mode a peak at m/z 755 [AgL2]- was observed, while the positive mode gave 
peaks at m/z 1062, 631 and 369 which correspond to Ag2L(PPh3)2+, Ag(PPh3)2+ and 
AgPPh3+, respectively. Again the HSAB theory supports the observations2.  
 
Figure 17. Crystal structure of the silver complex AgL(PPh3). 
 
In an effort to increase the coordination number on the silver atom, we then decided to 
use similar conditions to those used in formation of  the copper complex 31 i.e., by 
attaching phosphine ligands to the Ag metal before complexing the sulfonylimine ligand. 
We first prepared Ag(PPh3)3Cl 36 using the method of Sanghani93, in which AgCl is 
treated with triphenylphosphine in dichloromethane. The product was obtained as white 
crystalline solid and its melting point (185 °C) was consistent with the literature93. 
Treating ligand 15 with DBU and silver complex 36 in chloroform gave the desired 
product AgL(PPh3)2 17 as a yellow solid (Scheme 34). Recrystallization from 
ethanol/DCM mixture gave crystals suitable for X-ray diffraction (Appendix 6). The 
structure is similar to the one obtained for the copper(I) complex 31 and the mass 
  
spectrometry data has similar features to that of 31 and 35. The molecular ion peak was 
not observed in the spectrum but fragments at m/z 631 and 369 corresponding to 
[Ag(PPh3)2]+ and [AgPPh3]+ respectively, were observed. 
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Scheme 34. 
 
Moving down to the third row transition metals, we attempted to make PtL2 16 by 
modifying the method of Bhyrappa94. The platinum source was PtCl2(cyclooctadiene) 37, 
which has previously substituted its ligands for nitrogen ligands depending on the 
conditions. The complex 37 can substitute its cyclooctadiene (COD) ligand for two 
nitrogen ligands when refluxed with a ligand in toluene95, and can substitute all its 
ligands for four nitrogen ligands when refluxed in DMF94. We then decided to try the 
second method as it was expected to introduce four nitrogen ligands, coming from two 
chelating ligands 15.  
 
Treating ligand 15 with DBU and 37 in refluxing DMF did not yield any product. This is 
possibly due to the nature of our ligand which is not macrocyclic, as in previous studies93. 
We then decided to try out the first method to see if different results could be obtained 
and to our delight, a product was obtained. The product obtained however, was not the 
desired product 16. What we found was a platinum complex PtL(COD) 38, containing 
one chelate ligand 15 and the COD ligand (Scheme 35). This was confirmed by the 
crystal structure (Figure 18, appendix 7). Neutral nitrogen ligands were used to substitute 
the COD ligand95 and since our ligand 2 carries a negative charge, the chloride ligands 
are substituted first. 
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Scheme 35. 
 
 
Figure 18. Crystal structure of the platinum(II) complex 
 
The complex is neutral but since the ligand 15 carries a -1 charge, the COD ligand should 
also contribute a -1 charge. Crystal structure shows that the platinum has a sigma bond to 
a carbon and one double bond from COD has migrated to another carbon. This suggests 
that HCl is given off during the process in a mechanism still unknown. Mass 
spectrometry gave the parent peak at m/z 625 [M]+ confirming the formation of complex 
38. Other sources of platinum such as [PtCl4]2-, which is an analogue of [PdCl2Br2]2-, 
were not available to us and we could not make further attempts to synthesize the desired 
product 16. 
 
Attempts to make the gold complex 21 by treating ligand 15 with DBU and [AuCl4]- 
were unsuccessful. When treating the gold salt with ligand 15 following the above 
  
mentioned conditions a yellow oil was obtained but could not be characterized. No other 
gold salts we available to us thus no further experiments were carried. 
 
2.3.2 Comparison of the metal complexes with literature precedent 
 
We performed a Gmelin search to check for metal complexes with similar features to 
those synthesized. 4732 hits were found for copper(I) complexes with two chelate 
ligands, each having two nitrogen donor atoms, but no results were found for complexes 
with a sulfonyl-containing ligand. For the copper(I) complex, 527 hits were found for 
complexes with a bidentate ligand containing two nitrogen atoms and two 
triphenylphosphine units, but no hits were found for sulfonyl-containing ligands.  
 
Five-coordinate complexes were found for searches performed on both the cobalt(II) and 
zinc(II), but few results were obtained when compared to six and four-coordinate 
complex. 17 hits were found for complexes with two bidentate ligands and an axial 
ligand, all having nitrogen donor ligands, for cobalt(II) while 50 hits were found for 
zinc(II) complexes. 1403 hits were found for cobalt(II) complexes coordinated to six 
nitrogen atoms, while 845 hits were found for zinc(II) complexes. No hits were found for 
complexes with a sulfonyl-containing ligand.     
 
For the d8 metal ions, four-coordinate complexes with two bidentate nitrogen ligands 
were very common. 3273 hits were found for nickel(II) while 389 hits were found for 
palladium(II). No hits were found for complexes with a sulfonyl containing ligand.     
 
Silver(I) complexes with one bidentate nitrogen ligand and triphenylphosphine (TPP) 
unit(s) were found to be common. 33 hits were found for complexes having a bidentate 
ligand and two TPP units, while 166 hits were found for complexes having a bidentate 
ligand and one TPP unit. No hits were found for complexes with a sulfonyl containing 
ligand.     
 
  
Only three hits were found for a platinum complex having a bidentate nitrogen ligand and 
a cyclooctadiene (COD) ligand. The loss of one hydrogen atom and a shift of one double 
bond in the COD ring are also observed in these three complexes. No hits were found for 
complexes with a sulfonyl containing ligand.     
 
From the search results obtained, we observe that the complexes synthesized all posses 
similar features to those previously reported with the exception that the newly 
synthesized complexes contain a sulfonyl portion in their ligands.  
 
2.4 In vitro studies of the metal complexes 
 
The synthesized metal complexes were sent to Prof. C. Medlin’s laboratory for screening 
against cancer cells. The in vitro cytotoxic properties of the metal complexes were 
assessed by measuring the effect on proliferation of the tumour cell line, human 
adenocarcinoma of the cervix (HeLa). The HeLa cell lines are the most sensitive cancer 
cells and are usually used as the start point in finding active compounds. Active 
compounds are those with IC50 (concentration resulting in 50% inhibition of tumour 
growth) less than 10 µM36. The active compounds are then screened against resistant 
cancer cell lines and if they are still active, they undergo in vivo studies to test their 
toxicity toward the host. 
 
The metal complexes were incubated for seven days in the HeLa cells and the results are 
shown in table 1. The cell concentration was 5 × 102 cells per well, and the experiments 
were repeated three times for each compound. 
 
 
 
 
 
 
 
  
Table 1. In vitro results for the metal complexes. 
Drug IC50 (µM) ± SEM No exp done 
CuL(Ph3P)2  31 Was not done***   
CuL2 30 48.657 ± 1.343 3 
ZnL2DBU 33 44.82 ± 2.539 3 
CoL2DBU 32 17.855 ± 1.47 3 
NiL2 19 >50  3 
PdL2 34 Was not done***   
PtL(COD) 38 5.432 ± 1.96 3 
AgL(Ph3P)2 17 3.368 ± 0.488 3 
AgL(Ph3P)  35 4.363 ± 0.475 3 
Ag(Ph3P)3Cl 36 1.187 ± 0.023 3 
cisplatin 0.852 ± 0.117 3 
 *** Compounds did not dissolve in ethanol and could not be used in the study. 
 
None of the first row transition metal complexes showed activity against the HeLa cell 
line with IC50 values all above 10 µM. The three silver compounds were all active with 
IC50 less than 5 µM with 36 being the most active with IC50 1.187 µM. It appears from 
the results that the number of triphenylphosphines in the molecule enhances the activity 
of the compound. The complex 36 is the most active with three Ph3P groups followed by 
17 with two Ph3P groups and finally 35 with just one Ph3P group. 
 
 The platinum complex 38 was also active against the HeLa cell line but it had a high ± 
SEM value. The palladium complex was not soluble in ethanol as we experienced during 
the synthesis of the compound. What was surprising was the insolubility of the copper(I) 
complex which contains two triphenylphosphine units. We expected the Ph3P group to 
enhance solubility of a compound, but this appears to have favoured solubility in non-
polar solvents e.g. chloroform and DCM. The silver complexes containing the Ph3P 
groups were all soluble in ethanol, suggesting that the metal ion might also have an 
influence on the solubility of a compound. 
 
  
 None of the active compounds were more active than cisplatin which has an IC50 0.852 
µM, but they will be investigated for activity against resistant cancer cell lines. 
 
2.5 Magnesium amide bases in the synthesis of substituted N-heterocycles 
 
Our initial investigation was to extend the scope of the magnesiation protocol, using the 
method of Dinsmore et al.55, from pyrrole to indole. We first prepared the Grignard 
reagent isopropylmagnesium chloride (iPrMgCl) 15 by combining isopropyl chloride and 
magnesium in a 1.2: 1 ratio in tetrahydofuran (THF) at room temperature. The 
concentration of the base was determined by the method of Paquette96, and found to be 
0.9 M. We then repeated the magnesiation of N-phenylsulfonylpyrrole 5 by treating with 
iPrMgCl/ 5% iPr2NH and quenching with iodine (I2) to afford 2-iodo-N-
phenylsulfonylpyrrole 39 in 70% yield (Scheme 36). 
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Scheme 36. 
 
N-Phenylsulfonylindole 40 was subjected to the similar conditions and afforded 2-iodo-
N-phenylsulfonylindole 41 in 75% yield. Having made the iodoindole 41, we investigated 
the one-pot coupling reaction, in which 40 is treated with iPrMgCl/ 5% iPr2NH then 
Pd(Ph3)4 and arylhalide. Different 2-arylindoles were synthesized in this manner in a 
MSc work reported by Leboho97 (Scheme 37). These results concluded that the method is 
compatible with indole. 
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Scheme 37. 
 
We then reasoned that since tetramethylpiperidine (TMP) is much better than 
diisopropylamine in lithiation, using TMP in place of diisopropylamine (DA) may 
optimize this method. The number of equivalents of the Grignard may be reduced, the 
yields may increase and the reaction times may also be reduced. We began by repeating 
the preparation of iodosulfonylpyrrole 39 by modifying the general method by adding 
TMP in place of diisopropylamine. The product was obtained in less than 10% 
conversion, as shown from the 1H NMR spectrum. This could due to TMP being more 
bulky compared to DA; and since the amine base is used in catalytic amounts, the rate of 
regenerating the magnesium amide base is slower in TMP than in diisopropylamine. 
Increasing the mol % of TMP and reducing the amount of base did lead to improved 
yields (Table 2). Results by Dinsmore, using equimolar amounts of DA and iPrMgCl in 
preparation of 39 gave a 55% yield55, indicating that diisopropylamine is superior to TMP 
in magnesiation. 
 
 
 
  
Table 2. 
                                               
N
SO2Ph
N
SO2Ph
I
i) iPrMgCl; R2NH
ii)  I2
 
13 (mmol) iPrMgCl (mmol) R2NH (mmol) Yield (%) 
2.42  6.05 (2.5 eq.) 0.121 (5%) iPr2NH 
(18hrs) 
70 
2.49 6.08 (2.5 eq.) 0.123 (5%) TMP 
(18hrs) 
 9%a 
2.49 2.904 (1.2 eq.) 2.904 (1.2 eq) TMP 
(4hrs) 
39%a 
2.42 3.63 (1.5 eq) 0.242 (10%) TMP 
(18hrs) 
6%a 
a= yields quoted from 1H NMR 
 
The work by Knochel79-81 demonstrated a new generation of Hauser bases; 
R2NMgCl.LiCl, and Grignard reagents; iPrMgCl.LiCl 14 to be superior to the previously 
reported species. We were interested in modifying the Hauser bases and attempted to use 
the amine in catalytic amounts, as reported by Dinsmore55. The initial step was preparing 
the Grignard reagent iPrMgCl.LiCl, using the method of Knochel79-80, by which 
equimolar amounts of lithium chloride (LiCl) and magnesium (Mg) were mixed with 
excess isopropyl chloride in THF under argon. The concentration of the base was found 
to be 1.33 M, by the method of Paquette96. This is higher than the concentration of the 
first generation Grignard reagents, supporting the findings of Knochel that LiCl increases 
the solubility of the Grignard reagent in THF80-81. 
 
The initial investigation using iPrMgCl.LiCl 14 and catalytic amine, was the iodination of 
N-phenylsulfonylpyrrole 5. Results were compared with those reported by Dinsmore55. 
We began by finding optimum conditions for magnesiation, starting with catalytic TMP. 
Using 1.5 equivalents of 14 and 10 mol% TMP gave the iodopyrrole 39 in 19% yield. 
Replacing TMP with diisopropylamine gave 39 in 65% yield. Because these results 
  
suggest that catalytic diisopropylamine is superior to TMP, further optimizing conditions 
were done using diisopropylamine. Reducing the mol% of diisopropylamine to 5 mol% 
gave 39 in 48% yield. When reducing the amount of Grignard reagent to 1.2 equivalents 
and keeping the amine at 10 mol%, gave 39 in 40% yield. Increasing the Grignard 
reagent to 1.8 equivalents and keeping the amine at 10 mol% gave 39 in 72% yield, 
which is comparable to results reported by Dinsmore55 (Table 3). 
 
  Table 3. 
                             
N
SO2Ph
N
SO2Ph
I
i) iPrMgCl.LiCl; R2NH
ii)  I2
 
iPrMgCl.LiCl equivalent Amine mol% % yield  
1.5 10 (TMP) 19 
1.5 10 (Diisopropylamine) 65 
1.2 5 (Diisopropylamine) 48 
1.2 10 (Diisopropylamine) 40 
1.8 10 (Diisopropylamine) 72 
 
The downfall experienced with this method was the strength of the Grignard reagent with 
time. Repeating the above experiment with iPrMgCl.LiCl that was more than one week 
old gave yields lower than those initially obtained. Yields were reduced from 65% to 
30% using conditions from entry 2 (Table 3) and from 48% to 18% from entry 3. When 
looking at the state of the Grignard reagent, we observed precipitates at the bottom of the 
flask. Initially it was assumed the base was decomposing but, when checking the 
concentration, it had not changed. We then concluded that the LiCl was precipitating 
from the solution, resulting in formation of magnesiated dimers (Scheme 38), hence the 
strength is reduced.  
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Scheme 38. 
  
 
Stirring the solution for two hours before using the aged base solution gave improved 
results but could not reproduce the results obtained from a freshly prepared reagent. 
Yields improved from 30% to 53% (in entry 2) and from 18% to 40% (in entry 3) (Table 
3). Although the previous studies showed the Grignard reagent and Hauser bases to be 
stable for over a month79-80, our results show the best results are obtained using a freshly 
prepared reagent and yields drop as the Grignard reagent ages. 
 
Different N-heterocyclic compounds were subjected to the optimum conditions, 
mentioned above, and then iodine and dimethylformide (DMF) were added as 
electrophiles (Table 4). Treating 5 with 1.8 eq. iPrMgCl.LiCl/ 10% iPr2NH and quenching 
with DMF, gave 45 in 60% yield (entry 1b) which is higher than the previously reported 
using the method of Dinsmore55. The spectroscopic data of the product were comparable 
to previously reported results. 
 
 The iodoimidazole 47 was obtained from 46 in 78% yield (entry 2). Mass spectrometry 
gave the parent peak [M+, 100] and the fragment [193 corresponding to the loss of –
SO2NMe2]. 1H NMR gave two imidazole protons, while 13C NMR gave four carbon 
peaks corresponding to the desired product, thus we concluded that the desired product 
was formed. 
 
The 2-formylpyrrole 49 was obtained in 31% yield (entry 3). The compound was 
obtained as oil, and this came as a surprise since the starting material 48 (its preparation 
to be discussed later) was a solid. Sulfonyl groups are known promote crystallization of 
many compounds.  Mass spectrometry and NMR spectroscopy confirmed the formation 
of the product, however. A parent peak at m/z 202 [M]+, three pyrrole protons together 
with an aldehyde proton, and six carbon peaks, led us to conclude the right product was 
made.  
 
 
 
  
 
Table 4. 
N
SO2Ph
I2
N
SO2Ph
N
SO2Ph
I
O
N
N
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N
N
N
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N
I2 I
N
S OO
N
N
S OO
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O
N
SO2Ph
O
I2 N
SO2Ph
O
I
N
N
N
N
N
N
I
O
I2
72
60
78
31
85
85
70
1
2
3
4
5
entry substrate electrophile product Yield (%)
39
45
46 47
48 49
50 51
52 53
54
a.
b.DMF
a.
b. DMF
H
H
H
DMF
 
  
The iodoindole 51, prepared from indole 50, was obtained in 85% yield (entry 4) which is 
higher than the yield of iodoindole 41 obtained using the method of Dinsmore55 (75%). 
Mass spectrometry gave the parent peak at m/z 412 [M]+ and the fragment at m/z 271 [M 
–SO2Ph]+. 1H NMR spectrum gave signals which integrated to the correct compound and 
lead us to conclude that the right molecule has been made. Treating indole 50 with 1.8 eq. 
iPrMgCl.LiCl/ 10% iPr2NH and adding catalytic Pd(PPh3)4 together with iodobenzene, 
gave the 2-phenylindole 55 in 60% yield (figure 19). The product was obtained as an oil 
even though it contains a sulfonyl group and the starting material 50 is a solid. A parent 
peak at m/z 363 [M]+ is obtained from mass spectrometry. 1H NMR spectrum gave a 
singlet at δ 6.48 ppm which correspond to the proton in the 3-position. These results led 
us to conclude that the desired product has been formed and that the new method can be 
used for one pot coupling reactions. 
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 Figure 19. 
 
Deprotonation of N-benzylbenzimidazole 52 has been reported98-100, where lithium bases 
were employed. Treating 52 with 1.8 eq. iPrMgCl.LiCl/ 10% iPr2NH and quenching with 
I2 gave the iodoproduct 53 in 85% yield, while quenching with DMF gave 54 in 75% 
yield. The spectroscopic data for both compounds were comparable with literature 
results, and also the melting points were in agreement with literature98,100, leading to the 
conclusion that the right products were formed. 
 
Knochel reported the deprotonation of 3-chloroquinoline 56, at the 2 position83. We did 
not have 56 at our disposal so we used quinoline 57 instead. Treating 57 with 
iPrMgCl.LiCl/ 10% iPr2NH resulted in an immediate exothermic reaction and the flask 
had to be cooled down. Quenching with iodine did not the yield the 2-iodoquinoline 58 as 
expected. What was obtained was 2-isopropylquinoline 59 (Scheme 39). This was 
  
confirmed by mass spectrometry which showed a parent peak at m/z 172 [M + H]+. The 
1H NMR spectrum also showed the isopropyl protons.  
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Scheme 39. 
 
This suggests that iPrMgCl.LiCl acted as a nucleophile in a similar manner observed 
from the Tschitschibabin reaction101, where NaNH2 acts as nucleophile toward quinoline 
to give 2-aminoquinoline 60 (Figure 20). Similar results were obtained with pyridine as 
the substrate, where 2-isopropylpyridine 61 was formed. 
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Figure 20. 
 
Employing our method with the substituted benzene, ethyl-3-chlorobenzoate 62, resulted 
in addition to the ester group, giving 3-(3-chlorophenyl)-2,4-dimethylpentan-3-ol  63, 
instead of deprotonation at the 2-position (Scheme 40). This was confirmed by mass 
spectrometry where the parent peak at m/z 225[M - H]- was obtained when the instrument 
was run in negative ion mode.  
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Scheme 40. 
 
These results suggest that the Grignard reagent is reactive toward electrophiles but not 
basic enough to deprotonate, and hence should be converted into the less reactive and 
more basic magnesium amide base.   
 
2.6 Sulfonyl protecting groups 
 
Lastly we report differences between the two different sulfonyl protecting groups used in 
pyrrole and imidazole. The two were arylsulfonyl i.e., phenylsulfonyl and 
toluenesulfonyl, and N,N-dimethylsulfamoyl groups. The arylsulfonyl groups have been 
used extensively in pyrrole and indole protection41,55,57,60,102, and good yields were 
obtained over a variety of reactions. These protecting groups however, reduce the 
reactivity of imidazole and thus are not used as protecting groups for imidazole. We also 
observed this in our experiment when trying to react benzonitrile with lithiated 
phenylsulfonylimidazole 22 and found no products. 
 
 The use of N,N-dimethylsulfamoyl  protecting groups in pyrrole has been reported in 
substituted pyrrole58-59. Chadwick et al. showed the N,N-dimethylsulfamoyl  to be better 
  
protecting groups for imidazole61. The protecting group can be removed under basic 
conditions similar to those of removing arylsulfonyl protecting groups49,52,61. We were 
interested in introducing the N,N-dimethylsulfamoyl  protecting group into a free pyrrole 
and perform similar reactions performed on the arylsulfonylpyrrole. 
 
Preparation of the arylsulfonylpyrrole has already been reported in this chapter. The 
sulfamoylpyrrole 48 was prepared using the method of Wong et al.103 who treated a 
disubstistuted pyrrole with sodium hydride followed by N,N-dimethylsulfamoyl  chloride 
in DMF. We managed to get 48 in 99% yield using the method of Wong (Scheme 41). 
The 1H NMR spectrum gave two signals in the aromatic region corresponding to the four 
protons but since the molecule is symmetrical, only two peaks are observed. Mass 
spectrometry gave the parent peak at m/z 174 [M]+ and the fragment at m/z 108 which 
correspond to the [N,N-dimethylsulfamoyl]+. These led us to conclude the desired 
compound was made. When trying methods used for arylsulfonyl protection, no products 
were obtained. 
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Scheme 41. 
 
The sulfamoylimidazole 46 was prepared using the methods of Chadwick61. Imidazole is 
treated with triethylamine and N,N-dimethylsulfamoyl  chloride in benzene at room 
temperature (Scheme 42). The product was obtained in 78% yield. Spectroscopic data 
and melting point were similar to previously published data. 
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Scheme 42. 
 
The first comparison of the different protecting groups was in the iodination reaction; 
arylsulfonylpyrrole 5 and 8 iodination yield was in the range of 60-75% (Scheme 36), 
while arylsulfonylimidazole 22 could not be iodated (Scheme 43). The second 
comparison is the addition of benzonitrile to the lithiated arylsulfonylheterocycle; the 
yields for benzonitrile addition to arylsulfonylpyrrole ranged from 30-60% (Scheme 18) 
while no products were found in the addition to arylsulfonylimidazole (Scheme 19). 
Arylsulfonylpyrrole was methylated while its imidazole analogue could not be. These 
results led us to conclude that arylsulfonyl protecting groups are suitable for pyrrole and 
not for imidazole. 
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Scheme 43. 
 
Moving on to the N,N-dimethylsulfamoyl  protecting group; the sulfamoylpyrrole 48 
iodination was found to be 65% by 1H NMR analysis while the iodination of 
sulfamoylimidazole 46 was 78%. Methylation of sulfamoylpyrrole was not observed, 
while that of sulfamoylimidazole occured in 71% yield. The methods used for 
methylation were reported by Chadwick et al. and his results61 were comparable to those 
obtained in our laboratory. These results suggest the N,N-dimethylsulfamoyl  protecting 
group is suitable for both the imidazole and pyrrole but, it favours imidazole over pyrrole. 
 
  
From the above mentioned comparisons, both protecting groups are compatible with 
pyrrole but the arylsulfonyl protecting group is a better protecting group for pyrrole. The 
last reaction performed to support these observations was the benzonitrile addition to 
lithiated sulfamoylpyrrole 48. The reaction was performed under similar conditions to 
those for arylsulfonylpyrrole (Scheme 18), treating 48 with butyllithium followed by 
benzonitrile gave the sulfamide 64 in 25% yield (Scheme 44).  
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Scheme 44.  
 
1H NMR spectrum showed three pyrrole protons and mass spectrometry gave the parent 
peak [M+ 277] and the fragment [169 corresponding to the loss of N,N-
dimethylsulfamoyl]. These results led us to conclude that the correct molecule was made.  
We also concluded that arylsulfonyl chloride are better protecting groups for pyrrole 
when compared to N,N-dimethylsulfamoyl chloride. 
 
2.7 Conclusion and Recommendations 
 
In this dissertation, we were successful in achieving our aims. We started by investigating 
the 1,4-migration of the sulfonyl group during the synthesis of N-sulfonylimine ligands 6 
and 15. The investigation required the preparation of a 2-substituted N-
toluenesulfonylpyrrole 8 which is mixed with N-phenylsulfonylpyrrole 5 in the crossover 
experiment. Attempts to make a silyl and methyl substituted pyrrole did not yield the 
desired products in pure form. We were successful in preparing 2-phenyl-N-
toluenesulfonylpyrrole 26 in gram quantities using the method developed by Dinsmore et 
al. Other methods investigated for the preparation of 26 either required the reaction to be 
performed in a glove box or required a large excess of starting material for the reaction to 
occur. We then concluded that the method developed by Dinsmore et al. is superior over 
  
the current existing methods. When performing the crossover experiment, we found that 
the 1,4-migration of the sulfonyl group occurs via an intramolecular shift. 
 
The N-toluenesulfonylimine ligand 15 was successfully complexed with various 
transition metals and the metal complexes formed were sent for testing against cancer 
cells.  Although we intended that the metal ion should have a coordination number of 
four either by complexing two chelate ligands 15 or one chelate ligand with two 
triphenylphosphine units, as in the case for copper(I) and silver(I) metal ions, we 
observed metal complexes with coordination number of five, as in cobalt(II) 32 and 
zinc(II) 33, where in addition to the two chelate ligands a DBU unit is coordinated to the 
metal. When preparing the silver complex, we discovered that depending on the source of 
triphenylphosphine (TPP), we can produce metal complexes with one TPP unit 35 and 
also with two TPP units 17. The platinum complex 38 contains one chelate ligand 15 and 
a cyclooctadiene ligand as the second chelate ligand. The metal complexes that showed 
anti-cancer activity were the silver complexes and the platinum complex, and these 
complexes are currently undergoing further tests. 
 
We extended the scope of magnesiation, developed for the deprotonation of 
sulfonylpyrrole by Dinsmore et al., into sulfonylindole and found the method to work. 
Iodination of sulfonylindole was achieved in more than 70% yield, also the phenylation 
of sulfonylindole was achieved in more than 70% yield.  
 
Finally we investigated the magnesiation methodology recently developed by Knochel et 
al. which used a combination of  lithium chloride and Grignard reagent. We were 
interested in using catalytic amine base as opposed to the stochiometric amount required 
in the published report. We found that catalytic diisopropylamine was superior over 
tetramethylpiperidine, when using 10% mole equivalent, but found that the reaction time 
for deprotonation increases. The newly developed methodology was used to deprotonate 
N-sulfonylpyrrole, N-sulfonylindole, N-sulfonylimidazole and N-benzylbenzimidazole in 
moderate to good yields.  
 
  
For future work we recommend the following; 
- Solution studies on the complexes made, using UV-VIS and ESI mass 
spectrometry in trying to understand the stability and binding constants of the 
complexes in different media. This will be very important for the metal 
complexes which showed promising results as it might give insight on the mode 
of action of these compounds; 
- Further testing on the metal complexes against other diseases such as HIV and 
malaria, and also investigating the mode of action of the compounds;  
- Further investigation on the magnesiation methodology employing lithium 
chloride and catalytic amine and to try and use lithium chloride in catalytic 
amounts; 
- The total synthesis of the densely functionalized pyrolidine-aziridine ring system 
2 starting from N-sulfonylimine 4. This will require changing the nitrile source 
from benzonitrile to cyano-N,N-dimethylformamide or its derivatives, when 
reacting lithiated N-sulfonylpyrrole with nitriles. If the synthesis of 2 is 
successful, the total synthesis of azinomycin can be attempted. 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Chapter 3 
Experimental 
 
 
 
 
 
 
 
 
  
Chapter 3:                    Experimental 
 
3.1 General  
 
   a) Purification of reagents and solvents 
        - THF and diethyl ether were distilled from sodium/benzophenone 
        - Dichloromethane and DMF were distilled from calcium hydride 
        - Benzene and toluene were distilled from sodium 
        - Hexane and ethyl acetate were distilled without addition of reagents 
  
    b) Spectroscopic and Physical data 
 - Melting points were obtained using a Reichert hot-stage microscope, and are        
uncorrected 
-
 1H and 13C NMR spectra were recorded at 300.139 MHz and 75.035 MHz, 
respectively, on Bruker Avance-300 spectrometer. Spectra were recorded in 
deuteriated chloroform (CDCl3) unless otherwise specified. Chemical shifts are 
reported in parts per million (ppm) relative to tetramethylsilane as internal standard 
at zero ppm. The 1H NMR chemical shifts are reported: value (number of 
hydrogens, description of signal, coupling constant(s) in hertz (Hz) where 
applicable, assignment) and the 13C NMR chemical shifts are reported: value 
(assignment). Abbreviations used: s = singlet, d = doublet, t = triplet and m= 
multiplet. 
- Infrared spectra were obtained on Bruker Tensor 27 spectrometer. Samples were 
placed on a diamond tip. The absorptions are reported on the wavenumber (cm-1) 
scale, in the range 400 – 4000 cm-1. 
- High-resolution, low-resolution and fast atom bombardment (FAB) mass spectra 
were recorded on a VG70-SEQ instrument, electrospray ionization (ESI) mass 
spectra were recorded on a Thermo Fischer LXQ instrument. Data are quoted: m/z 
value (relative abundance). Samples ran on FAB were dissolved in a 3-nba matrix, 
while those in ESI were dissolved in a ethanol/water mixture. 
  
- The crystal structure data sets was obtained on a Bruker SMART 1K CCD area 
detector diffractometer with graphite monochromator Mo Kα radiation (50 kV, 30 
mA). 
 
 c) Nomenclature and numbering of compounds 
The compounds prepared during the course of this project are named in the 
following experimental section according to systematic nomenclature. However, the 
numbering system used to illustrate the diagrams of these compounds is one 
adopted for convenience and is not meant to reflect systematic numbering of these 
compounds. 
 
3.2 Synthetic procedures 
 
Isopropylmagnesium chloride (iPrMgCl) 13 
 
A flame dried three neck round bottom flask containing Mg (4.89 g, 0.201 mol) pre-dried 
under high vacuum at 90 °C for 50 minutes, was fitted with a dropping funnel containing 
isopropyl chloride (30 ml, excess), reflux condenser, and  250 ml flask containing dry 
THF (200 ml) via a cannula. THF (50 ml) was transferred to the flask followed by 
isopropyl chloride (~6 ml) and few crystals of iodine. The flask was heated to initiate the 
reaction and placed in an ice-water bath once the reaction started. The remaining 
isopropyl chloride was added drop-wise at such a rate to maintain a gentle reflux and the 
resulting solution was stirred at room temperature until all Mg has reacted. The final 
solution was diluted with dry THF, allowed to settle and transferred into a dry Ar flushed 
flask via a cannula. The concentration of the solution was determined using the method 
of Paquette83. In a flame dried, one-neck round bottomed flask, menthol (0.312 g, 2 
mmol) and 1,10-phenanthroline (4mg) were dissolved in dry THF and stirred for 2 
minutes under Ar. The Grignard solution was added drop-wise via syringe until a distinct 
violet color persisted for longer than a minute. The concentration was found to be 0.91 
M. 
 
  
Isopropylmagnesium chloride- lithium chloride (iPrMgCl.LiCl)  14 
 
The base was prepared using the method of Knochel67-68. Mg (2.673 g, 110 mmol) and 
anhydrous LiCl (4.25 g, 100 mmol) were dried under high vacuum at 90 °C for 30 
minutes. Isopropyl chloride (9.14 ml, 100 mmol) dissolved in dry THF (50 ml) was 
added slowly added into the flask along with few crystals of I2 and the mixture stirred 
under Ar at room temperature. The reaction which starts within a few minutes was kept at 
room temperature and left stirring for 16 hours. The concentration was determined as 
mentioned above, and found to be 1.33 M. 
 
N-Toluenesulfonylpyrrole  8 
                                                                         
N
S OO
 
                                                           
In a flame dried flask, pyrrole (5 ml, 0.07 mol) and NaOH (8.4 g, 0.21 mol) were 
suspended in dry DCM (50 ml) and stirred at room temperature for 5 minutes to give a 
finely divided mixture. p-Toluenesulfonyl chloride (19 g, 0.1 mol), dissolved in  DCM 
(40 ml), was added to the mixture, the flask was capped with a drying tube and stirred at 
room temperature for 48 hours. The reaction was quenched with water, the resulting 
solution extracted with  DCM (3 × 50 ml), the combined organic layers washed with 
brine (15 ml), dried over MgSO4, filtered and the solvent was removed under reduced 
pressure to give a brown solid which was purified by column chromatography, eluting 
with hexane / EtOAc (80 :20). N-Toluenesulfonylpyrrole was isolated as a brown-tan 
solid, (12.578 g, 81.3%); mp 93-95 °C (Lit87. 98-100oC); νmax (NaCl) /cm-1 3054 (m), 
1596 (m, C=N), 1455 (m), 1371 (m),1265 (s) and 1189 (m, -SO2-); δH (300 MHz; CDCl3; 
Me4Si) 7.98 (2H, d, J 7.8, Ar-H), 7.29 (2H, d, J 7.3, Ar-H), 7.15 (2H, m, Pyrrole-H), 6.28 
(2H, m, pyrrole-H) and 2.40 (3H, s, -Me); δC (75 MHz; CDCl3) 142.9, 134.1, 127.9, 
124.8, 118.7, 111.5 and 19.6; LREI m/z 221 (M+, 100), 155 (32), 91 (71) and 65 (18).  
  
N-Phenylsulfonylpyrrole  5 
                                                        
N
S OO
 
 
The above method was repeated using phenylsulfonyl chloride as an electrophile. After 
purification, N-phenylsulfonylpyrrole was isolated as a grey solid, (7.635 g, 50%); mp 
82-84 oC (Lit88. 87-88 oC); νmax (NaCl / cm-1) 3054 (m), 1596 (m, C=N), 1455 (m), 1371 
(m),1265 (s) and 1189 (m, -SO2-); δH (75 MHz; CDCl3; Me4Si) 7.85 (2H, t, J 2.3, pyrrole 
-H), 7.57 (3H, m, Ar-H), 7.17 (2H, m, Ar-H), 6.30 (2H, t, J 2.3, pyrrole-H); δC (75 MHz; 
CDCl3) 139.5, 134.2 , 129.8 , 127.14, 121.2  and 114; m/z 207 (M+, 70), 141 (35), 115 
(5), 77 (100) and 51 (16) (Found: 207.0343. C10H9NSO2 requires 207.03540). 
 
N,N-Dimethylsulfamoyl chloride 
 
Using the variation to the methods of Hendrickson89, N,N-dimethylamine hydrochloride 
(30 g, 0.369 mol)  was added to a 250 ml r.b. flask. The flask was then placed in an ice-
bath then sulfuryl chloride (SO2Cl2) (99.6 g, 0.729 mol) was added drop-wise over 5 
minutes into the flask. The flask was then capped with a drying tube and gently refluxed 
for 24 hours. The excess SO2Cl2 was removed under reduced pressure then dry THF (45 
ml) was added to precipitate the unreacted N,N-dimethylamine hydrochloride. The 
solution was filtered through a plug of celite, then THF removed under reduced pressure 
to give a clear oil which was purified by distillation to give the title compound as a clear 
oil (45.953 g, 89.6 %). b.p 54 oC at 2.8 mmHg (Lit.89 67 oC at 8 mmHg); δH (300 MHz; 
CDCl3; Me4Si) 2.693 (6H, s, Me);  δC (75 MHz; CDCl3) 39.5914; (LREI) m/z 143.6 (M+ , 
50), 108.1 (100).  
 
 
  
N,N-Dimethyl-1H-pyrrole-1-sulfonamide  48 
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NaH (1.22 g, 0.05 mol) was suspended in DMF (20 ml) and placed in an ice bath. Pyrrole 
(2.63 ml, 0.0368 mol) was added drop-wise into the solution where a thick creamy 
solution formed. N,N-Dimethylsulfamoyl chloride (4.36 ml, 0.041mol) was added drop-
wise at 0 oC over 5 minutes, then the resulting mixture was allowed to warm to room 
temperature and left stirring for 4 hours. DMF was removed under high vacuum. The 
resulting dark oil was partitioned between EtOAc/water (1: 1) (50 ml), the organic layer 
extracted, the aqueous layer washed twice more with EtOAc (20 ml). The combined 
organic layers were washed with brine (10 ml), dried over MgSO4, and the solvent 
removed to give a dark oil which crystallized upon standing to give a black solid. The 
solid was then dissolved in DCM and filtered through silica plug to give N,N-Dimethyl-
1H-pyrrole-1-sulfonamide (6.356 g, 99%) of a light brown solid. mp. 55 ºC; δH (300 
MHz; CDCl3; Me4Si) 7.08 (2H, m, pyrrole H), 6.31 (2H, m, pyrrole H), 2.81 (6H, s, -
Me); δC (75 MHz; CDCl3) 124.1, 112.1, 38.6; LREI m/z 174 (M+, 80), 108 (100), 68 (93). 
 
N,N-Dimethylimidazole-1-sulfonamide  46 
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Using the method of Chadwick48, imidazole (3.010 g, 0.0528 mol), triethylamine (6 ml, 
0.043 mol) and N,N-dimethylsulfamoyl chloride (6 ml, 0.055 mol) were dissolved in 
benzene (40 ml) and stirred at room temperature for 20 hours. The mixture was filtered 
and the precipitate washed with benzene (2 x 15 ml). The filtrate and the washings were 
combined and the solvent removed under reduced pressure to give a clear oil which was 
dried under vacuum to give N,N-dimethylimidazole-1-sulfonamide (7.563 g, 78%) as a 
  
white solid; mp 40-42˚C (lit.48 42-44˚C) ; νmax (NaCl / cm-1) 3127 (w), 1625.4 (w), 1391 
(m)1153 (m, -SO2-); δH (300 MHz; CDCl3; Me4Si) 7.92 (1H, s, imidazole-2-H), 7.27 (1H, 
s, imidazole-4-H), 7.16 (1H, s, imidazole-5-H) and 2.86 (6H, s, -Me); δC (75 MHz; 
CDCl3) 137.1, 130.9, 118.1 and 38.5; LREI m/z 175 (M+, 30), 108 (100), 69.2 (20). 
 
N,N-Dimethyl-2-methylimidazole-1-sulfonamide48       
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Following the method of Chadwick48, the sulfonamide 46 (0.5 g, 2.9 mmol) was 
dissolved in dry THF (10ml) and the solution cooled to -78 oC in a N2/ acetone bath, n-
BuLi (1.6 M, 2.19 ml, 3.5 mmol) was added and the resulting solution stirred for 15 
minutes at -78˚C. The reaction was quenched with iodomethane (0.3 ml, 4.8 mmol). The 
stirring was continued at room temperature for 20 hours and the mixture was extracted 
with 2M HCl (5 x 12ml). The combined acidic solutions were washed once with Et2O (10 
ml) and basified with 10% NaOH solution. The solution was saturated with NaCl, 
extracted five times with chloroform (10 ml), the combined organic phase dried over 
MgSO4 and the solvent removed to give N,N-dimethyl-2-methylimidazole-1-sulfonamide 
as a brown mobile oil (0.39 g , 71%). δH (300 MHz; CDCl3; Me4Si); 7.22 (1H, d, J 1.7 
Hz, imidazole 4-H), 6.93 (1H, d, J 1.7 Hz, imidazole 5-H),  2.91( 6H, s, NMe2), 2.63 (3H, 
s, Me); δC (75 MHz; CDCl3) 145.7, 130.5, 119.7, 38.2 and 15.3; LREI m/z  189.1 (M+, 
38), 108.1 (100), 83.2 (26) and 54.3 (9). 
 
General Method for Magnesation  
Method A65 
To N-toluenesulfonyl pyrrole 8 was added iPrMgCl (0.86 M, 2.5 eq. with respect to 8, in 
THF) and (iPr)2NH (0.05 eq. with respect to 8). The mixture was maintained at room 
  
temperature under an argon atmosphere for 18 hours. An electrophile (2 eq. with respect 
to 8) was added and the mixture was stirred at room temperature. The reaction was 
quenched by addition of saturated aqueous NH4Cl (20 ml), and a saturated Na2S2O3 
solution (20 ml) in the case of I2 as an electrophile. The mixture was extracted three times 
with EtOAc, the organic layer was dried over MgSO4, filtered and the solvent was 
removed under reduced pressure. Further details are given for each individual 
preparation, described below. 
Method B 
To an N-heterocycle was added a solution of iPrMgCl.LiCl (1.11M, 1.8 eq. with respect 
to N-heterocycle, in THF) and (iPr)2NH (0.1 with respect to N-heterocycle). The mixture 
was stirred at room temperature under an argon atmosphere for 18 hours. An electrophile 
was added and the mixture was stirred at room temperature for 20 minutes. The reaction 
was quenched by addition of saturated aqueous NH4Cl (20 ml), and a saturated Na2S2O3 
solution (20 ml) in the case of I2 as an electrophile. The mixture was extracted three times 
with EtOAc, the organic layer was dried over MgSO4, filtered and the solvent was 
removed under reduced pressure. 
 
2-Iodo- N-Phenylsulfonylpyrrole 39 
                                                           
N
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N-Phenylsulfonylpyrrole 5 (1.00 g, 4.82 mmol) was treated according to method A, with 
iPrMgCl (12.05 mmol, 14 ml, 2.5 eq.) and (iPr)2NH (28 µl, 0.2 mmol, 5 mol %). After 
standing at room temperature for 18 hours, the reaction was treated with I2 (3.00 g, 12.0 
mmol) followed by aqueous work-up and recrystallized from 96% EtOH  to give 2-iodo  
- N-phenylsulfonylpyrrole 39 (1.12 g, 70% ) as brown crystals; mp. 96-98 (Lit.65 97-98) 
  
δH (300 MHz; CDCl3; Me4Si) 7.91-7.94 (2H, m, Ar-H), 7.61-7.66 (1H, m, Ar-H), 7.59 
(1H, dd, J 3.4 and 1.8, pyrrole-H), 7.50-7.56 (2H, m, Ar-H), 6.52 (1H, dd, J 3.4 and 1.8, 
pyrrole-H), and  6.27 (1H, apparent t, J 3.4, pyrrole-H); δC (75 MHz; CDCl3) 147.5, 
138.2, 134.2, 129.2, 128.1, 127.9, 126.7 and 114.6;  HREI m/z 333 (M+ , 85), 207 (7), 192 
(9), 141 (46) and 77 (100) (Found: 332.9392. C10H8NO2SI requires 332.9321). 
The reaction was also performed using method B and 2-iodo- N-phenylsulfonylpyrrole 
was obtained in 68% yield. Spectroscopic and physical properties obtained, were 
identical to those reported above. 
 
2-Phenyl- N-toluenesulfonylpyrrole  26 
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 N-Toluenesulfonylpyrrole 8 (0.884 g, 3.98 mmol) was treated according to method A, 
with iPrMgCl (0.86 M, 9.95 mmol, 2.5 eq.) and (iPr)2NH (28 µl, 0.2 mmol, 5 mol %). 
Iodobenzene (0.89 ml, 7.96 mmol) and Pd(Ph3P)4 (0.231 g, 0.2 mmol). After stirring at 
room temperature for 48 hours, the reaction was partitioned between EtOAc (50 ml) and 
sat. aq. NH4Cl (50 ml), the organic phase separated, the aqueous phase washed further 
with EtOAc. The combined organic phase were dried over MgSO4 and the solvent 
removed under reduced pressure to give a brown oil which was further purified by 
column chromatography on silica gel, eluting with dichloromethane / hexane (1:4) to 
yield the title compound as a brown solid (600 mg, 51%) mp. 122 ˚ C  (Lit. 123-124 ˚C)77 
δH (300 MHz; CDCl3; Me4Si) 7.05-7.44 (10H, m, 9Ar-H and 1 pyrrole-H), 6.30 (1H, 
apparent t, J 3.3, pyrrole-H), 6.15 (1H, apparent dd, J 1.8 and 3.3, pyrrole-H) and 2.35 
(3H, s, Me);   δC (75 MHz; CDCl3) 145.0, 136.4, 136.0, 131.7, 131.3, 129.7, 128.6, 127.7, 
127.5, 124.5, 116.1, 112.4 and 21.9; HREI m/z 297.08 (M+, 100).  
  
N-Phenylsulfonylpyrrole-2-carbaldehyde 45 
                                                           
N
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N-Phenylsulfonylpyrrole (2.42 mmol, 0.50 g) was treated according to method B with 
iPrMgCl.LiCl (4.356 mmol, 3.92 ml, 1.8 eq) and (iPr)2NH (0.242 mmol, 34 µl, 10 
mol%). DMF (6 mmol, 0.31 ml) was added and the solution stirred for 30 min. The 
aqueous work-up gave a brown oil which was purified with column chromatography on 
silica gel using 20% EtOAc: hexane as eluent to give N-phenylsulfonylpyrrole-2-
carbaldehyde (0.344 g, 60%) as an off-white solid; mp 77-78 ºC (Lit90., mp. 78-79 ºC); δH 
(300 MHz; CDCl3; Me4Si) 9.96 (1H, s, CHO), 7.94-7.91 (2H, m, Ar-H), 7.67-7.46 (4H, 
m, pyrrole-H and Ar-C), 7.18 (1H, dd, J 3.4 and 1.7, pyrrole-H) and 6.43 (1H, apparent t, 
J 3.4, pyrrole-H); δC (75 MHz; CDCl3) 179.2 (CHO), 138.6, 134.9, 133.9, 129.8, 127.8, 
125.2 and 112.9;  HREI m/z 235.03 (M+, 100). 
 
1-Benzyl-2-iodo-1H-benzo[d]imidazole 53 
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N-Benzylbenzimidazole (2.42 mmol, 0.503 g) was treated according to method B with  
iPrMgCl.LiCl (4.356 mmol, 3.92 ml, 1.8eq) and (iPr)2NH (0.242 mmol, 34 µl, 10 mol%). 
I2 (6 mmol, 1.50 g) was added and the solution stirred for 10 min. The aqueous work-up 
gave a brown solid which was purified with column chromatography on silica gel using 
20% EtOAc: hexane as eluent to give 1-benzyl-2-iodo-1H-benzo[d]imidazole (0.686 g, 
85%) as a white solid; mp 118-119 ºC (Lit.84 118-120 oC); δH (300 MHz; CDCl3; Me4Si)  
  
7.75 (1H, t, J 3.0, benzimidazole-H), 7.32-7.13 (8H, m, benzimidazole-H and Ar-H), 5.38 
(2H, s, -CH2-); LREI m/z 334.8 (M + H, 15), 333.8 (M+, 100), 207 (25). 
 
1-benzyl-1H-benzo[d]imidazole-2-carbaldehyde 54 
                                                           
N
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 N-Benzylbenzimidazole (2.42 mmol, 0.503 g) was treated according to method B with 
iPrMgCl.LiCl (4.356 mmol, 3.92 ml, 1.8 eq) and (iPr)2NH (0.242 mmol, 34 µl, 10 
mol%). DMF (6 mmol, 0.31 ml) was added and the solution stirred for 30 min. The 
aqueous work-up gave a brown oil which was purified with column chromatography on 
silica gel using 20% EtOAc in hexane as eluent to give 1-benzyl-1H-benzo[d]imidazole-2 
-carbaldehyde (0.406 g, 70%) as a white-yellow solid; mp 104-105 ºC (lit.86 105-107 oC);  
δH (300 MHz; CDCl3; Me4Si) 10.141 (1H, s, CHO), 7.95 (1H,t , J 3.0, benzimidazole-H), 
7.44-7.15 (8H, m, benzimidazole-H and Ar-H), 5.85 (2H, s, -CH2-); δC (75 MHz; CDCl3) 
184.9 (CHO), 145.9, 142.9, 136.6, 136.0, 128.9, 128.0, 127.1, 126.937, 124.2, 122.5, 
111.4 and 48.0; HREI m/z 236.09 (M+, 100). 
 
2-Iodo-N,N-dimethyl-1H-imidazole-1-sulfonamide  47 
                                                           
N
N
S OO
N
I
 
N,N-Dimethylimidazole-1-sulfonamide (2.42 mmol, 0.420 g) was treated according to 
method B with iPrMgCl.LiCl (4.356 mmol, 3.92 ml, 1.8eq) and (iPr)2NH (0.242 mmol, 
34 µl, 10 mol%) and left stirring at room temperature for 18 hrs. I2 (6.0 mmol, 1.50 g) 
was added and the solution stirred for 10 min. The aqueous work-up gave a dark brown 
oil which was purified with column chromatography on silica gel using 20% EtOAc: 
Hexane as eluent to give 2-iodo-N,N-dimethyl-1H-imidazole-1-sulfonamide (0.568 g, 
78%) as brown oil. δH (300 MHz; CDCl3; Me4Si) 7.45 (1H, d, J 1.8, imidazole-H), 7.05 
  
(1H, d, J 1.8, imidazole-H), 2.98 (6H, s, -Me); δC (75 MHz; CDCl3) 131.2, 123.5, 83.2 
and 37.8; LREI m/z 301.9 (M + H, 5), 300.9 (M+, 100), 193.9 (29).(Found 300.9376: 
C5H8N3SO2I requires 300.9382). 
 
2-Formyl-N,N-dimethylpyrrole-1-sulfonamide 49 
                                                         
N
S OO
N
O
   
N,N-Dimethyl-1H-pyrrole-1-sulfonamide (2.42 mmol, 0.417 g) was treated according to 
method B with  iPrMgCl.LiCl (4.356 mmol, 3.92 ml, 1.8eq) and (iPr)2NH (0.242 mmol, 
34 µl, 10 mol%) and left stirring at room temperature for 18 hrs. DMF (6 mmol, 0.31 ml) 
was added and the solution stirred for 30 min. The aqueous work-up gave a brown oil 
which was purified with column chromatography on silica gel using 40% EtOAc in 
hexane as eluent to give 2-formyl-N,N-dimethylpyrrole-1-sulfonamide (0.151 g, 31%) as 
a brown oil. Vmax 1665 (CHO), 1421 (C=O), 1379, 1249 and 1153 (-SO2-); δH (300 MHz; 
CDCl3; Me4Si) 10.06 (1H, s, CHO), 7.40 (1H, apparent t, J 1.7, pyrrole-H), 7.27-7.23 
(1H, m, pyrrole-H), 6.39 (1H, apparent t, J 3.3, pyrrole-H) and 2.87 (6H, s, -Me); δC (75 
MHz; CDCl3) 179.9 (CHO), 133.9, 129.9, 122.5, 111.4 and 38.2; m/z HREI 202.0408 
(M+, 100) (Found 202.0408: C7H10O3N2S requires 202.0412). 
 
2-Iodo-5-methoxy-1phenylsulfonyl-1H-indole 51 
                                                   
N
O
I
S OO
 
5-Methoxy-1-phenylsulfonyl-1H-indole (2.42 mmol, 0.695 g) was treated according to 
method B with iPrMgCl.LiCl (4.356 mmol, 3.92 ml, 1.8eq) and (iPr)2NH (0.242 mmol, 
34 µl, 10 mol%) and left stirring at room temperature for 18 hrs. I2 (6 mmol, 1.5 g) was 
added and the solution stirred for 10 min. The aqueous work-up gave a dark brown oil 
  
which was purified with column chromatography on silica gel using 10% EtOAc in 
hexane as eluent to give 2-iodo-5-methoxy-1-phenylsulfonyl-1H-indole (0.849 g, 85%) 
as a brown solid; mp. 122-124˚C; δH (300 MHz; CDCl3; Me4Si)  8.18 (1H, d, J 8.2, Ar-
H), 7.87 (2H, d, J 7.9, Ar-H), 7.55-7.53 (1H, m, indole-H), 7.46-7.41 (2H, m, Ar-H), 
6.93-6.85 (3H, m, indole-H) and 3.83 (3H, s, -OMe); δC (75 MHz; CDCl3) 156.9, 138.5, 
134.4, 133.7, 133.1, 129.5, 127.5, 124.8, 116.8, 114.2, 102.4 and 56.0; LREI m/z 414.8 
(M + H, 12), 412.8 (M+, 79), 271.8 (100) and 228.8 (10) (Found 412.9585: C15H12NO3SI 
requires 412.9582). 
 
5-Methoxy-2-phenyl-1-phenylsulfonyl-1H-indole 55 
                                                           
N
O
S OO
 
5-Methoxy-1-phenylsulfonyl-1H-indole (2.42 mmol, 0.695 g) was treated according to 
method B with iPrMgCl.LiCl (4.356 mmol, 3.92 ml, 1.8eq) and (iPr)2NH (0.242 mmol, 
34 µl, 10 mol%) and left stirring at room temperature for 18 hrs. The reaction was treated 
with iodobenzene (0.49 ml, 4.356 mmol) and Pd(Ph3P)4 (231.16 mg, 0.2 mmol). After 
stirring at room temperature for 48 hours, the reaction was partitioned between EtOAc 
(50 ml) and sat. aq. NH4Cl (50 ml), the organic phase separated, the aqueous phase 
washed further with EtOAc (25 ml). The combined organic phase were dried over 
MgSO4 and the solvent removed under reduced pressure to give a brown oil which was 
further purified by column chromatography on silica gel, eluting with dichloromethane / 
hexane (1:4) to yield the title compound as a brown oil (0.527 g, 60%); δH (300 MHz; 
CDCl3; Me4Si) 8.19 (1H, d, J 9, Ar-H), 7.51-7.24 (10H, m, Ar-H and indole-H),  6.96 
(1H, dd, J 2.4 and 9, indole-H), 6.88 (1H, d, J 2.4, indole-H), 6.48 (1H, s, indole-H) and 
3.814 (3H, s, -OMe); δC (75 MHz; CDCl3) 157.1, 143.0, 137.2, 133.4, 132.8, 132.3, 
131.7, 130.2, 128.7, 128.5, 127.5, 126.7, 117.7, 113.9, 113.5, 103.2 and 55.6; HREI m/z 
363.09 (Found 363.0924: C21H17O3NS requires 363.0929). 
  
2-(4-Bromo-2,5-dimethoxyphenyl)-1-phenylsulfonyl-1H-indole  44 
                                                     
N
S OO
Br
O
O
 
1-Phenylsulfonyl-1H-indole (2.42 mmol, 0.622 g) was treated according to method A 
with iPrMgCl (6.05 mmol, 2.5 eq.) and (iPr)2NH (28 µl, 0.2 mmol, 5 mol %). After 
standing at room temperature for 18 hours, the reaction was treated with 1,4-dibromo       
-2,5-dimethoxybenzene (4.356 mmol, 1.280g) and Pd(Ph3P)4 (231.16 mg, 0.2 mmol). 
After stirring at room temperature for 48 hours, the reaction was partitioned between 
EtOAc (50 ml) and sat. aq. NH4Cl (50 ml), the organic phase separated, the aqueous 
phase washed further with EtOAc. The combined organic phase were dried over MgSO4 
and the solvent removed under reduced pressure to give a brown oil which was further 
purified by column chromatography on silica gel, eluting with EtOAc / hexane (1:5) to 
yield the title compound as a brown solid (0.706 g, 62%) mp. 181-183˚C; δH (300 MHz; 
CDCl3; Me4Si) 8.24 (1H, d, J 8.4, Ar-H), 7.51 -7.25 (8H, m, Ar-H and indole-H), 7.13 
(1H, s, Ar-H), 6.78 (1H, s, Ar-H), 6.58 (1H, s, indole-H), 3.82 (3H, s, -OMe) and 3.68 
(3H, s, -OMe); δC (75 MHz; CDCl3) 153.1, 149.6, 139.0, 137.9, 137.0, 133.8, 130.4, 
129.0, 127.1, 125.2, 124.3, 121.5, 121.3, 116.7, 116.5, 116.1, 113.5, 113.3, 57.4 and 56.5 
; HREI m/z 471.01 (Found 471.0151: C22H18O4NBrS requires 471.0139). 
 
4-Methyl-N-[phenyl(1H-pyrrol-2yl)methylene]benzenesulfonamide 15  
                                                       
H
N
N
S
O
O
R
R = H; 6
R = Me; 15
 
Using variation methods to Mandy and Patil42, N-toluenesulfonylpyrrole 8 (1.004g, 
0.0046 mol) was dissolved in dry THF (20 ml), the flask was cooled to –20 °C in N2/ 
  
acetone bath. n-BuLi (1.6 M, 3.25 ml, 0.0052 mol, 1.2 eq) was added and the solution 
stirred at –20ºC for 20 minutes. Benzonitrile (0.6 ml, 0.0055 mol) was added and the final 
solution was allowed to warm to room temperature and stirred for 17 hours. The reaction 
was quenched with saturated NH4Cl solution, and extracted with EtOAc (2 × 20 ml). The 
combined organic layers were washed with brine, dried over MgSO4 and the solvent 
removed under reduced pressure to give a brown oil, which was further purified by 
column chromatography, eluting with hexane / EtOAc (80 : 20) to give the title 
compound (0.894 g, 60%); mp 110-113˚C; νmax (NaCl / cm-1) 3358 (m, N-H), 3058 (m), 
1595 (w, C=N), 1545 (s) and 1197 (s, -SO2); δH (300 MHz; CDCl3; Me4Si) 10.16 (1H, 
broad s, -NH),  7.75 (2H, d, J 7.846, Ar-H), 7.52-7.36 (5H, m, Ar-H), 7.26-7.21 (4H, m, 
Ar-H), 6.48 (1H, m, pyrrole-H), 6.30 (1H, m, pyrrole-H) and 2.43 (3H, s, -Me);  δC (75 
MHz; CDCl3) 142.0, 137.9, 131.1, 129.6, 126.6, 126.1, 111.2 and 20.6; HREI m/z 324 
(M+, 37), 259  (70), 169 (100), 157 (24), 91 (42) and 77 (31) (Found 324.09237. 
C18H16O2N2S requires 324.09325). 
 
N-[Phenyl(1H-Pyrrol-2yl)methylene]benzenesulfonamide  6 
Repeating the above procedure with N-phenylsulfonylpyrrole 5 gave the title compound 6 
(0.423 g, 30%) ; mp 145-148˚C; νmax (NaCl / cm-1) 3428 (m, N-H), 3055 (m), 1544 (s) 
and 1156 (s); δH (300 MHz; CDCl3; Me4Si) 10.16 (1H, broad s, -NH), 7.99-7.82 (2H, m, 
pyrrole-H), 7.70-7.38 (8H, m, Ar-H), 7.25 (2H, m, Ar-H), 6.51 (1H, m, pyrrole-H), 6.33 
(1H, m, pyrrole-H); δC (75 MHz; CDCl3) 141.8, 132, 130.7, 129.6, 129.3, 128.6,  128.0, 
127.7 and 112.3; HREI m/z 31.01003 (M+, 46), 249.1169 (10), 169.0698 (100) and 
77.03945 (38) (Found 310.01003, C17H14N2O2S requires 310.0776).         
                                           
 
 
 
 
  
 (E)-4-Methyl-N-[phenyl(5-phenyl-1H-pyrrol-2-yl)methylene]benzenesulfonamide 
29  
                                                     
H
N
N S
O
O
 
2-Phenyl-N-tolueneulfonylpyrrole 26 (420 mg, 1.4 mmol) was dissolved in dry THF 
(5ml), the flask was cooled to –20 °C, in N2/ acetone bath, n-BuLi (1.1 ml, 1.69 mmol) 
was added and the solution stirred at –20 °C for 30 minutes. Benzonitrile (1.69 mmol, 
0.19 ml) was added and the final solution was allowed to warm to room temperature and 
stirred for 2 hours. The reaction was quenched with saturated NH4Cl solution, and 
extracted with EtOAc (2 × 20 ml). The combined organic layers were washed with brine, 
dried over MgSO4 and the solvent removed under reduced pressure to give a brown oil, 
which was further purified by column chromatography, eluting with hexane / EtOAc (80 : 
20) to give (200 mg, 36%) of the title compound. Mp. 114˚C δH (300 MHz; CDCl3; 
Me4Si) 10.80 (1H ,broad s, NH), 7.71 (4H,dd, J 17.31 and 7.32,p-Tol-H), 7.35-7.52 (8H, 
m, Ar-H), 7.21-7.26 (2H, m, Ar-H), 6.61 (1H, apparent t, J 3.3, pyrrole-H)  6.54 (1H, m, 
pyrrole-H), 2.41 (3H,s,me); δC (75 MHz; CDCl3) 143.4, 142.8, 139.3, 131.0, 130.6, 
129.9, 128.0, 127.5, 125.9, 110.5, 21.9; HREI m/z 400.13245 (M+,80), 245.11597 (100), 
218.98562 (62) and 115.02906 (58) (Found 400.13245: C24H20N2O2S requires 400.1245). 
 
N,N-Dimethyl-N’-[phenyl(1H-pyrrol-2yl)methylene]sulfamide  64 
                                                            
H
N
N
S
O
O N
 
N,N-Dimethyl-1H-pyrrole-1-sulfonamide 48 (2.9 mmol, 0.501 g) was lithiated as 
mentioned above for the preparation of 15, using n-BuLi (3.45 mmol, 2.2 ml) at –20 °C 
and stirred for 30 minutes before the addition of benzonitrile (3.45 mmol, 0.35 ml). The 
  
final solution was allowed to warm to room temperature and left stirring for 2 hours. The 
usual aqueous work-up gave a dark oil which was purified by column chromatography 
using 20% EtOAc: hexane as eluent to give the title compound (0.202 g, 25%) as a brown 
solid; mp. 106-108 °C; δH (300 MHz; CDCl3; Me4Si) 7.60-7.41 (5H, m, Ar-H), 7.20 (1H, 
m, pyrrole-H), 6.50 (1H, m, pyrrole-H), 6.31 (1H, m, pyrrole-H) and 2.90 (6H, s, -Me); 
δC (75 MHz; CDCl3) 130.8, 129.1, 128.6, 128.3, 127.4, 111.7 and 38.9; HREI m/z 
278.18047 (M + H+, 8), 277.177 (M+, 40), 169.121 (100) and 77.053 (21) (Found 
277.17715: C13H15N3O2S requires 277.0885). 
 
Crossover experiment 
 
In a flame dried flask, 2-phenyl-N-tolueneulfonylpyrrole 26 (210 mg;0.7 mmol)  and N-
phenylsulfonyl pyrrole 5 (144.9 mg; 0.7 mmol) were dissolved in dry THF (5 ml). The 
flask was cooled to –20 °C, in N2/ acetone bath, n-BuLi (1.1 ml, 1.69 mmol) was added 
and the solution stirred at –20 °C for 30 minutes. Benzonitrile (1.69 mmol, 0.19 ml) was 
added and the final solution was allowed to warm to room temperature and stirred for 2 
hours. The reaction was quenched with saturated NH4Cl solution, and extracted with 
EtOAc (2 × 20 ml). The combined organic layers washed with brine, dried over MgSO4 
and the solvent removed under reduced pressure to give a brown oil which was purified 
by chromatography using 10% EtOAc in hexane as eluent. Two fractions were collected 
and characterized by high resolution MS which showed the presence of (E)-4-methyl-N-
[phenyl(5-Phenyl-1H-pyrrol-2-yl)methylene]benzenesulfonamide and  N-[phenyl(1H-
pyrrol-2yl)methylene]benzenesulfonamide as the products of the addition reaction. 
   
Metal Complexes 
 
Ligand 1 = deprotonated  4-methyl-N-[phenyl(1H-pyrrol-
2yl)methylene]benzenesulfonamide   
 
 
 
  
 
CuL(P(Ph)3)2  31 
 
Ligand 1 (0.100 g, 0.301 mmol) and CuBr(P(Ph)3)3 (0.263 g, 0.301 mmol) were 
dissolved in chloroform (20 ml)and stirred for 2 minutes. DBU (45 µl, 0.301 mmol) was 
added to the solution by syringe and the resulting solution, which turned from light 
brown to dark brown, was left stirring at room temperature for 30 minutes. The reaction 
was quenched with sat. NHCO3, washed with DCM, the organic layer dried over MgSO4. 
The solvent was removed to give a dark brown oil which was dissolved in DCM: hexane 
(1: 1, 10 ml) to precipitate yellow crystals (160 mg, 58%)  suitable for X-Ray diffraction. 
(See Appendix 3 for structure); mp.(dec.) 193-195ºC;  νmax  3053 (w), 1522 (s), 1481 (s, 
C=N), 1463 (s), 1433 (s), 1413(s), 1361 (s), 1297 (s), 1267 (vs), 1195 (w, -SO2-), 1143 
(vs); δH (300 MHz; CDCl3; Me4Si) 7.39-7.16 (31H, m, P(Ph)3 and pyrrole-H), 7.04 (3H, t, 
J 7.8, Ar-H), 6.87 (2H, d, 7.5, Ar-H), 6.50-6.40 (4H, m, Ar-H), 6.23 (1H, apparent d, J 
3.4, pyrrole-H), 5.29 (1H, m, pyrrole-H) and 2.17 (3H, s, -Me); Anal. Calcd. for 
C54H45CuN2O2P2S: C, 71.15; H, 4.98; N, 3.07; S, 3.52.  Found: C, 69.56; H, 5.14; N, 
3.03; S 3.70. FAB m/z 587.4 (M minus L)+ (15), 325.2 (15), 262.2 (25); ESI 587.25 (100) 
 
CuL2  30 
 
Ligand 1(0.200 g, 0.617 mmol) and Cu(OAc)2 (56.11 mg, 0.3085 mmol) were dissolved 
in methanol (10 ml) and stirred for 2 minutes, DBU (90 µl, 0.617 mmol) was added to the 
solution which was then refluxed for 2 hours. The solution was then allowed to cool to 
room temperature whereafter precipitation occurred. The precipitates were filtered, 
washed with methanol (5ml) and allowed to dry to afford dark green crystals (75 mg, 
34%). mp.(dec.) >250 °C; νmax  1596 (w), 1541 (vs), 1490 (s, -C=N), 1470 (w), 1443 (w), 
1405 (s), 1369 (vs), 1317 (s), 1283 (vs), 1219 (s), 1201 (vs, -SO2-), 1182 (s), 1151 (vs), 
1108 (s) 1044 (vs), 1005 (s); m/z ESI 732.13 (M + Na+, 10), 710.08 (M + H+, 12), 347.12 
(L + Na+, 100) and  325.03 (L + H+). 
 
 
  
 
NiL2  19 
 
Ligand 1 (0.400 g, 1.24 mmol) and Ni(acetylacetonate)2 (0.159 g , 0.62 mmol) were 
dissolved in ethanol (10 ml), DBU (1.24 mmol, 180 µl) was added and the final solution 
was refluxed for 24 hours. The solution was allowed to cool to room temperature. The 
solvent was reduced to half its original volume and the solution was left in the fridge 
overnight whereafter precipitation occurred. The precipitates were filtered, washed with 
diethyl ether (10 ml), recrystallised from DCM: hexane mixture to give light green 
crystals (128 mg, 29%). mp.(dec) 149-151ºC;  νmax 1645 (s), 1580 (s), 1523 (m), 1487 
(m, C=N), 1465 (m), 1443 (m), 1417 (s), 1366 (w), 1281 (s), 1196 (s, -SO2-), 1148 (s), 
1086 (s), 1034 (s); FAB m/z 727.2 (M + Na+, 20), 705.2 (M + H+), 381.1 (5), 325.1 (55). 
 
CoL2DBU 32 
 
Ligand 1 (0.200 g, 0.617 mmol) and CoCl2.6H2O (73.76 mg, 0.31 mmol) were dissolved 
in methanol (10 ml), DBU (90 µl, 0.617 mmol) was added to the solution which was 
refluxed for 24 hours and cooled to room temperature. The solvent was reduced to half 
and the solution was left in the fridge for 24 hours whereafter precipitation occurred. The 
precipitates were filtered off, washed with methanol (5 ml), then petroleum ether (10 ml) 
and left to dry in air to give a brown solid (160mg, 60%). The solid was recrystallised 
from DCM: EtOH mixture to afford dark crystals suitable for X-Ray diffraction (See 
appendix 4 for structure). mp.(dec) > 250ºC; νmax 1599 (s), 1526 (s), 1489 (s, C=N), 1465 
(s), 1429 (s), 1380 (s), 1312 (vs), 1273 (vs), 1214 (vs), 1194 (s, -S02), 1155 (vs), 1082 (s), 
1042 (vs), 1003 (s); FAB m/z 858.2 (M + H+, 5), 705.2 (8), 534.2 (36), 153.1 (100). 
 
ZnL2DBU 33 
 
Ligand 1 (0.200 g, 0.617 mmol) and ZnCl2 (42.16 mg, 0.31 mmol) were dissolved in 
methanol (10 ml). DBU (90 µl, 0.617 mmol) was added to the solution which was 
refluxed for 24 hours, then cooled to room temperature. The solvent was reduced to half 
  
and the solution was left in the fridge for 24 hours whereafter precipitation occurred. The 
precipitates were filtered off, washed with methanol (5 ml), then petroleum ether (10 ml) 
and left to dry in air to give a brown solid (160mg, 60%). mp.(dec) 228-230º ;  νmax 1646 
(w), 1599 (s), 1524 (s), 1490 (s, C=N), 1468 (s), 1432 (vs), 1379 (vs), 1310 (vs), 1276 
(s), 1215 (vs), 1199 (s, -SO2-), 1153 (vs), 1082 (s), 1042 (vs), 1003 (s); ESI m/z 733.48 
(6), 711.17 (10), 603.22 (20), 347.10 (100); FAB 863.2 (M + H+, 5), 711.2 (5), 539.2 
(30), 387.1 (5), 325.1 (7), 153.2 (100). 
 
AgLP(Ph)3 35 
 
Ligand 1 (0.227 g, 0.855 mmol), silver nitrate (0.145 g, 0.855 mmol) and P(Ph)3 (0.244 g, 
0.885 mmol) were dissolved in ethanol (10 ml) and stirred for 2 minutes. DBU (0.855 
mmol, 125 µl) was added to the solution, which was refluxed in the dark under Ar for 4 
hours. The solution was allowed to cool to room temperature whereafter precipitation 
occurred. The precipitates were filtered, washed with EtOH (2 ml), diethyl ether (10 ml) 
and allowed to dry in air to give a dark green solid (340 mg, 61%) which was 
recrystallised in DMF-DCM mixture to give light green crystals suitable for X-Ray 
diffraction (See Appendix 5 for structure). mp.(dec.) 218-220 °C; νmax 1738 (s), 1592 (w), 
1435 (m), 1366 (s), 1229 (s), 1216 (s); δH (300 MHz; CDCl3; Me4Si) 7.64-7.14 (23H, m, 
PPh3 and Ar-H), 6.84 (2H, d, J 7.8, Ar-H), 6.41-6.37 (2H, m, pyrrole-H) and 2.26 (3H, s,-
Me); δC (75 MHz; CDCl3) 168.4 , 145.6 , 142.1, 141.2, 140.3, 135.8, 134.6, 134.4, 131.9, 
131.4, 131.1, 129.5, 129.4, 129.4, 128.9, 128.5, 127.5, 126.9, 116.9 and 21.8; Anal. Calcd 
for C36H30AgN2O2PS: C, 62.34; H, 4.36; N, 4.04; S, 4.62. Found: C, 59.93; H, 4.46; N, 
4.05; S, 4.74.; m/z FAB 631.4 (100), 369.2 (70), 325.2 (40). 
 
AgCl[P(Ph)3]3  36 
 
AgCl (1.49 g, 10 mmol) was suspended in DCM (140 ml) then P(Ph)3 (10.97 g, 40 mmol) 
dissolved in DCM (40 ml) was added drop-wise into the solution. The final solution was 
stirred at room temperature for 2 hours, filtered, hexane added to the filtrate until the 
solution turned milky. The Ag complex precipitates out upon standing and was filtered, 
  
washed with hexane and dried in air to give white crystals (7.52 g , 81%). m.p 185 oC 
(Lit. 185-187 oC)80   
 
AgL[P(Ph)3]2 17 
 
Ligand 1 (0.277 g, 0.855 mmol) and AgCl[P(Ph)3]3 (0.795 g, 0.855 mmol) were 
dissolved in chloroform (20 ml), DBU (0.855 mmol, 0.125 µl) was added to the solution. 
The final solution was stirred at room temperature for 30 minutes, washed with sat. 
NaHCO3 (10 ml) extracted with DCM (10 ml × 2), the combined organic layers were 
dried over Na2SO4, and the solvent removed to leave a dark brown oil. The oil was 
dissolved in DCM: hexane (1:4) where unreacted AgCl[P(Ph)3]3 was precipitated out as 
white solid (300 mg). The filtrate was again dissolved in DCM: Hexane mixture, at which 
point yellow precipitates (340 mg, 42%) were obtained. The solid was recrystallised from 
EtOH: DCM where crystals suitable for X-Ray diffraction were obtained (see appendix 6 
for structure); mp. (dec) 226-230 °C; νmax 1739 (s,br), 1597 (w), 1521 (s), 1480 (w, 
C=N), 1465 (s), 1433 (w), 1408 (s), 1371 (vs), 1323 (m), 1291 (s), 1265 (s), 1197 (s, -
SO2-), 1155 (s), 1141 (s), 1081 (s), 1048 (m)1031 ( s);  δH (300 MHz; CDCl3; Me4Si) 
7.43-7.25 (33 H, m, PPh3 and Ar-H), 7.13-6.91 (4H, m, Ar-H), 6.86 (2H, d, J 7.8, Ar-H), 
6.64 (2H, d, J 7.8, Ar-H), 6.40 (1H, apparent d, J 3.9, pyrrole-H), 6.29- 6.28 (1H, m, 
pyrrole-H) and 2.20 (3H, s, -Me); FAB m/z 631.4 (M minus L)+ (69), 369.2 (80), 262.2 
(100); (Anal. calcd. for C51H45AgN2O2P2S: C, 67.86; H, 4.75; N, 2.93; S, 3.35: Found C, 
65.67; H, 4.82; N, 2.58, S, 2.95. 
 
PdL2  34 
 
Ligand 1 (0.2 g, 0.617 mmol) was dissolved in MeOH (10 ml). NaOAc (24 mg, 0.31 
mmol) was added to the solution which was stirred for 5 minutes. In a separate flask, 
PdCl2 (54.72 mg, 0.31 mmol) and LiBr (107.68 mg, 1.24 mmol) were dissolved in MeOH 
(2 ml) and stirred for 2 minutes before being transferred to the other flask. The final 
solution was stirred at 30ºC for 24 hours. Yellow precipitates, which started forming in 
the first hour, were collected by filtration, washed with methanol then petroleum ether to 
  
give a yellow solid (140 mg); mp.(dec) >250 °C; νmax 1595 (w), 1577 (w), 1547 (s), 1490 
(w, C=N), 1444 (w), 1399 (s), 1365 (s), 1323 (s), 1293 (s), 1219 (w), 1196 (m, -SO2), 
1152 (s), 1084 (s), 1043 (s), 1010 (m); ESI m/z 775.1 (M + Na+, 34), 347.11 (L + Na+, 
100), 325.08 (L + H+, 5). 
 
PtL(COD)  38 
 
Ligand 1 (259.8 mg, 0.804 mmol) and PtCl2(COD) (150 mg, 0.402 mmol) were dissolved 
Toluene (20 ml), DBU (117.6 µl, 0.804 mmol) was added and the resulting solution was 
refluxed under Ar for 12 hours. The solution was filtered, the solvent removed by 
evaporation and the resulting yellow oil was purified by column chromatography using 
20% EtOAc in hexane as eluent. A bright yellow solid (156 mg) was obtained and 
recrystallised from DCM: EtOH mixture to give crystals suitable for X-Ray diffraction 
(see appendix 7 for structure); mp. (dec) 204-206 °C; νmax 1597 (w), 1529 (s), 1491 (m, 
C=N). 1468 (m), 1406 (m), 1373 (s), 1322 (s), 1292 (s), 1250 (w), 1218 (w), 1197 (w, -
SO2), 1155 (s), 1080 (m), 1048 (s), 1016 (m); FAB m/z 625.4 (M+, 62), 518.3 (5), 470.3 
(25), 364.2 (12), 325.2 (25).   
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